

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199925965 B2
(10) Patent No. 759391

(54) Title
Pneumococcal and meningococcal vaccines formulated with interleukin-12

(51)⁶ International Patent Classification(s)
A61K 039/09 A61K 039/385
A61K 039/095 A61K 039/39

(21) Application No: 199925965 (22) Application Date: 1999 . 02 . 10

(87) WIPO No: WO99/40936

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/074528	1998 . 02 . 12	US

(43) Publication Date : 1999 . 08 . 30
(43) Publication Journal Date : 1999 . 11 . 04
(44) Accepted Journal Date : 2003 . 04 . 10

(71) Applicant(s)
American Cyanamid Company

(72) Inventor(s)
Vincent J. Laposta; John H. Eldridge

(74) Agent/Attorney
SPRUSON and FERGUSON,GPO Box 3898,SYDNEY NSW 2001

(56) Related Art
US 5866134
WO 98/14871
US 6303114

25965/99

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/09, 39/095, 39/39, 39/385		A2	(11) International Publication Number: WO 99/40936
			(43) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/US99/02847		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 February 1999 (10.02.99)			
(30) Priority Data: 60/074,528 12 February 1998 (12.02.98) US 60/074,528 12.02.98 US			
(71) Applicant: AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).			
(72) Inventors: LAPOSTA, Vincent, J.; 24 Bromley Road, Pittsford, NY 14534 (US). ELDRIDGE, John, H.; 4 Beatrice Cove, Fairport, NY 14450 (US).			
(74) Agent: BROWN, Scott, A.; American Home Products Corporation, Patent and Trademark Dept. -2B, Attn: Brady, Kay, E., One Campus Drive, Parsippany, NJ 07054 (US).			
		Published Without international search report and to be republished upon receipt of that report.	
<div style="border: 1px solid black; padding: 5px; display: inline-block;">IP AUSTRALIA 30 AUG 1999 RECEIVED</div>			
(54) Title: PNEUMOCOCCAL AND MENINGOCOCCAL VACCINES FORMULATED WITH INTERLEUKIN-12			
(57) Abstract <p>This invention pertains to vaccine compositions comprising a mixture of antigen, such as a pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated to a carrier molecule. These vaccine compositions modulate the protective immune response to the antigen.</p>			

PNEUMOCOCCAL AND MENINGOCOCCAL VACCINES
FORMULATED WITH INTERLEUKIN-12

BACKGROUND OF THE INVENTION

5 The immune system uses many mechanisms for
attacking pathogens; however, not all of these
mechanisms are necessarily activated after immunization.
Protective immunity induced by vaccination is dependent
on the capacity of the vaccine to elicit the appropriate
immune response to resist or eliminate the pathogen.
10 Depending on the pathogen, this may require a cell-
mediated and/or humoral immune response.

15 The current paradigm for the role of helper T cells
in the immune response is that they can be separated
into subsets on the basis of the cytokines they produce,
and that the distinct cytokine profile observed in these
cells determines their function. This T cell model
includes two major subsets: TH-1 cells that produce IL-
2 and interferon γ (IFN- γ) which augment both cellular
and humoral immune responses, and TH-2 cells that
20 produce IL-4, IL-5 and IL-10 which augment humoral
immune responses (Mosmann et al., *J. Immunol.* 126:2348
(1986)). It is often desirable to enhance the
immunogenic potency of an antigen in order to obtain a
stronger immune response in the organism being immunized
and to strengthen host resistance to the antigen-bearing
25 agent. A substance that enhances the immunogenicity of
an antigen with which it is administered is known as an
adjuvant. For example, certain lymphokines have been

Shown to have adjuvant activity, thereby enhancing the immune response to an antigen (Nencioni *et al.*, *J. Immunol.* 139:800-804 (1987); EP285441 to Howard *et al.*).

Summary of The Invention

This invention pertains to vaccine compositions comprising a mixture of one or more pneumococcal or meningococcal antigens, the interleukin IL-12 and a mineral in suspension. The IL-12 can be either adsorbed onto the mineral suspension or simply mixed therewith. In a particular embodiment of the invention, the IL-12 is adsorbed onto a mineral suspension such as alum (e.g., aluminum hydroxide or aluminum phosphate). These vaccine compositions modulate the protective immune response to the antigen; that is, the vaccine composition is capable of quantitatively and qualitatively improving the vaccinated host's antibody response, and quantitatively increasing cell-mediated immunity for a protective response to a pathogen. In a particular embodiment of the invention, the antigen is a pneumococcal or meningococcal antigen; the antigens are optionally conjugated to a carrier molecule, such as in a pneumococcal or meningococcal glycoconjugate.

Thus, according to a first aspect of this invention there is provided a vaccine composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum and optionally comprising a physiologically acceptable vehicle.

According a second embodiment of this invention there is provided a method of eliciting an immune response to a pneumococcal antigen, comprising administering to a mammalian host an effective amount of a vaccine composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

According to a third embodiment of this invention there is provided a method of enhancing IFN- γ response to a pneumococcal vaccine, comprising administering to a mammalian host an effective amount of a vaccine composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising, alum and optionally comprising a physiologically acceptable vehicle.

According to a fourth embodiment of this invention there is provided a method of eliciting complement-fixing antibodies for a protective response to a pathogen, comprising administering to a mammalian host an effective amount of an immunogenic composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.




According to a fifth embodiment of this invention there is provided an immunogenic composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

5 According to a sixth embodiment of this invention there is provided a vaccine composition comprising a mixture of a meningococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

10 According to a seventh embodiment of this invention there is provided a method of eliciting an immune response to a meningococcal antigen, comprising administering to a mammalian host an effective amount of a vaccine composition comprising a mixture of a meningococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

15 According to an eighth embodiment of this invention there is provided an immunogenic composition comprising a mixture of a meningococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

20 Studies described herein show that IL-12 can modify the humoral response of mice immunized with pneumococcal and meningococcal glycoconjugate vaccines formulated with aluminum phosphate ($AlPO_4$). The particular pneumococcal polysaccharide serotypes exemplified herein are serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F, (Pn1, Pn4, Pn5, Pn6B, Pn9V, Pn14, Pn18C, Pn19F, Pn23F),



-3-

and the meningococcal polysaccharide is type C (Men C). These serotypes, however, are not to be construed to limit the scope of the invention, as other pneumococcal and meningococcal serotypes are also suitable for use herein. Moreover, it will be apparent to the skilled artisan that conjugation to a carrier molecule, such as the CRM₁₉₇ protein exemplified herein, is optional, depending upon the immunogenicity of the selected pneumococcal or meningococcal antigen.

Doses of IL-12 ranging from about 8 ng to about 1,000 ng increased the IgG1, IgG2a, IgG2b and IgG3 response to alum-adsorbed Pn14 or Pn6B. In addition they increased the IgG2a response to Pn4 and Pn9V. Doses of IL-12 of about 5,000 ng markedly reduced the overall IgG titers to Pn14, and especially the IgG1 and IgG2b titers.

The invention also pertains to methods for preparing an immunogenic composition or a vaccine composition comprising a mixture of antigen and IL-12 with a mineral in suspension. In particular, the IL-12 is adsorbed onto the mineral suspension. The invention also pertains to methods for eliciting or increasing a vaccinee's IFN- γ -producing T cells and complement-fixing IgG antibodies for a protective immune response, comprising administering to a mammalian, e.g., human or primate, host an effective amount of a vaccine composition comprising a mixture of antigen, IL-12 and a mineral in suspension in a physiologically acceptable solution. In particular, the IL-12 is adsorbed onto the mineral suspension.

SUBSTITUTE SHEET (rule 26)

-4-

DETAILED DESCRIPTION OF THE INVENTION

Work described herein reveals the ability of IL-12 to increase the immune response to alum-based pneumococcal vaccines, particularly serotype 14 and serotype 6B pneumococcal glycoconjugate vaccines, and meningococcal vaccines, particularly type C, to increase the proportion of complement-fixing IgG2a and IgG2b antibodies. As described herein, PnPs-14-CRM₁₉₇ vaccine comprises a serotype 14 pneumococcal polysaccharide conjugated to a non-toxic mutant of diphtheria toxoid (cross-reacting material) designated CRM₁₉₇, and PnPs6B-CRM₁₉₇ vaccine comprises a serotype 6B pneumococcal polysaccharide conjugated to CRM₁₉₇. IL-12 was compared to MPL® (3-O-deacylated monophosphoryl lipid A; RIBI ImmunoChem Research, Inc., Hamitton, Montana), which in mice is a potent adjuvant for pneumococcal vaccines. In a separate experiment conducted in Balb/c mice, the effect of IL-12 on the cytokine profile of the CRM-specific T cells induced by the exemplary conjugate vaccines on alum was examined.

IL-12 is produced by a variety of antigen-presenting cells, principally macrophages and monocytes. It is a critical element in the induction of TH-1 cells from naive T cells. Production of IL-12 or the ability to respond to it has been shown to be critical in the development of protective TH-1-like responses, for example, during parasitic infections, most notably Leishmaniasis (Scott et al., U.S. Patent No. 5,571,515). The effects of IL-12 are mediated by IFN- γ produced by NK cells and T helper cells. Interleukin-12 (IL-12),

SUBSTITUTE SHEET (rule 26)

-5-

originally called natural killer cell stimulatory factor, is a heterodimeric cytokine (Kobayashi et al., *J. Exp. Med.* 170:827 (1989)). The expression and isolation of IL-12 protein in recombinant host cells is described in International Patent Application WO 90/05147, published May 17, 1990.

The studies described herein reveal the utility of IL-12 as an adjuvant in a pneumococcal or meningococcal vaccine, and particularly a pneumococcal or meningococcal glycoconjugate vaccine. Accordingly, this invention pertains to vaccine compositions comprising a mixture of such an antigen, IL-12 and a mineral in suspension. In a particular embodiment of the invention, the IL-12 is adsorbed onto a mineral suspension such as alum (e.g., aluminum hydroxide or aluminum phosphate). These vaccine compositions modulate the protective immune response to the antigen; that is, the vaccine composition is capable of eliciting the vaccinated host's complement-fixing antibodies for a protective response to the pathogen. In a particular embodiment of the invention, the antigen is a pneumococcal antigen, particularly a pneumococcal polysaccharide; the pneumococcal antigen is optionally conjugated to a carrier molecule, such as in a pneumococcal glycoconjugate. The particular pneumococcal polysaccharide serotypes exemplified herein are serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F; however, these serotypes are not to be construed to limit the scope of the invention, as other serotypes are also suitable for use herein.

SUBSTITUTE SHEET (rule 26)

-6-

In another embodiment of the invention, the antigen is a meningococcal antigen, particularly a meningococcal polysaccharide; the meningococcal antigen is optionally conjugated to a carrier molecule, such as in a meningococcal glycoconjugate. Type C *Neisseria meningitidis* is exemplified herein; however, this type is not to be construed to limit the scope of the invention, as other types are also suitable for use herein.

IL-12 can be obtained from several suitable sources. It can be produced by recombinant DNA methodology; for example, the gene encoding human IL-12 has been cloned and expressed in host systems, permitting the production of large quantities of pure human IL-12. Also useful in the present invention are biologically active subunits or fragments of IL-12. Commercial sources of recombinant human and murine IL-12 include Genetics Institute, Inc. (Cambridge, MA).

The antigen of this invention, e.g., a pneumococcal or meningococcal antigen or a pneumococcal or meningococcal glycoconjugate, can be used to elicit an immune response to an antigen in a mammalian host. For example, the antigen can be a serotype 14 or 6B pneumococcal polysaccharide or a portion thereof which retains the ability to stimulate an immune response. Additional suitable antigens include polysaccharides from other encapsulated bacteria and conjugates thereof, secreted toxins and outer membrane proteins.

The method comprises administering to the mammal, e.g., human or primate, an immunologically effective

SUBSTITUTE SHEET (rule 26)

-7-

dose of a vaccine composition comprising a mixture of an antigen, such as a pneumococcal antigen or a pneumococcal conjugate, and an adjuvant amount of IL-12 adsorbed onto a mineral in suspension.

5 As used herein, an "immunologically effective" dose of the vaccine composition is a dose which is suitable to elicit an immune response. The particular dosage of IL-12 and the antigen will depend upon the age, weight and medical condition of the mammal to be treated, as
10 well as on the method of administration. Suitable doses will be readily determined by the skilled artisan. The vaccine composition can be optionally administered in a pharmaceutically or physiologically acceptable vehicle, such as physiological saline or ethanol polyols such as
15 glycerol or propylene glycol.

 The vaccine composition may optionally comprise additional adjuvants such as vegetable oils or emulsions thereof, surface active substances, e.g., hexadecylamin, octadecyl amino acid esters, octadecylamine,
20 lysolecithin, dimethyl-dioctadecylammonium bromide, N,N-dioctadecyl-N'-N'-bis (2-hydroxyethyl-propane diamine), methoxyhexadecylglycerol, and pluronic polyols; polyamines, e.g., pyran, dextran sulfate, poly IC, carbopol; peptides, e.g., muramyl dipeptide,
25 dimethylglycine, tuftsin; immune stimulating complexes; oil emulsions; liposaccharides such as MPL® and mineral gels. The antigens of this invention can also be incorporated into liposomes, cochleates, biodegradable polymers such as poly-lactide, poly-glycolide and poly-
30 lactide-co-glycolides, or ISCOMS (immunostimulating

SUBSTITUTE SHEET (rule 26)

-8-

complexes), and supplementary active ingredients may also be employed. The antigens of the present invention can also be administered in combination with bacterial toxins and their attenuated derivatives. The antigens of the present invention can also be administered in combination with other lymphokines, including, but not limited to, IL-2, IL-3, IL-15, IFN- γ and GM-CSF.

The vaccines can be administered to a human or animal by a variety of routes, including but not limited to parenteral, intradermal, transdermal (such as by the use of slow release polymers), intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal routes of administration. The amount of antigen employed in such vaccines will vary depending upon the identity of the antigen. Adjustment and manipulation of established dosage ranges used with traditional carrier antigens for adaptation to the present vaccine is well within the ability of those skilled in the art. The vaccines of the present invention are intended for use in the treatment of both immature and adult warm-blooded animals, and, in particular, humans. Typically, the IL-12 and the antigen will be co-administered; however, in some instances the skilled artisan will appreciate that the IL-12 can be administered close in time but prior to or after vaccination with the antigen.

The pneumococcal and meningococcal antigens of the present invention can be coupled to a carrier molecule in order to modulate or enhance the immune response. Suitable carrier proteins include bacterial toxins

SUBSTITUTE SHEET (rule 26)

-9-

rendered safe by chemical or genetic means for administration to mammals and immunologically effective as carriers. Examples include pertussis, diphtheria, and tetanus toxoids and non-toxic mutant proteins (cross-reacting materials (CRM)), such as the non-toxic variant of diphtheria toxoid, CRM₁₉₇. Fragments of the native toxins or toxoids, which contain at least one T-cell epitope, are also useful as carriers for antigens, as are outer membrane protein complexes. Methods for preparing conjugates of pneumococcal antigens and carrier molecules are well known in the art and can be found, for example, in Dick and Burret, *Contrib Microbiol Immunol.* 10:48-114 (Cruse JM, Lewis RE Jr, eds; Basel, Krager (1989)) and U.S. Patent No. 5,360,897 (Anderson et al.).

The adjuvant action of IL-12 has a number of important implications. The adjuvanticity of IL-12 can increase the concentration of protective functional antibodies produced against the antigen in the vaccinated organism. The use of IL-12 as an adjuvant can enhance the ability of antigens which are weakly antigenic or poorly immunogenic to elicit an immune response. It may also provide for safer vaccination when the antigen is toxic at the concentration normally required for effective immunization. By reducing the amount of antigen, the risk of toxic reaction is reduced.

Typically, vaccination regimens call for the administration of antigen over a period of weeks or months in order to stimulate a "protective" immune

SUBSTITUTE SHEET (rule 26)

-10-

response. A protective immune response is an immune response sufficient to protect the immunized organism from productive infection by a particular pathogen or pathogens to which the vaccine is directed.

5 As shown in the Examples, in an alum-formulated vaccine, comprising IL-12 adsorbed onto AlPO₄ and a serotype 14 or serotype 6B pneumococcal polysaccharide conjugated to CRM₁₉₇, which normally induces a response dominated by IgG1, 0.2 µg of IL-12 substantially
10 increased the IgG2a and IgG3 subclasses in both Balb/c and Swiss Webster mice, but had little or no effect on IgG1. Enhancement of IgG2b to Pn14 was seen with Swiss Webster mice; 0.2 µg of IL-12 had the same effect as 25 µg of MPL® on the IgG subclass response to Pn14,
15 suggesting that IL-12 is at least 100-fold more biologically active than MPL® in this regard. As expected from the IgG subclass distribution, especially the enhanced IgG2a response, the opsonophagocytic activity of the antisera for Pn14 pneumococci from mice
20 receiving 0.2 µg IL-12 was higher than that of controls and was equivalent to that of mice immunized with vaccine formulated with a much larger amount of MPL®.

Briefly, IgG2a and IgG2b antibodies are very efficient at activating the complement system, whereas
25 IgG1 antibodies are not. The complement system consists of a series of plasma proteins which come together around IgG2a or IgG2b bound to antigen (e.g., bacteria) to form a large molecular complex. Deposition of this complex on the surface of bacteria results in the
30 killing of the bacteria by perforating the cell membrane

SUBSTITUTE SHEET (rule 26)

-11-

(bactericidal activity) or by facilitating the recognition of the bacteria by phagocytic cells (such as polymorphonuclear cells (PMN) used in this study), which take up the bacteria and kill them (opsonophagocytosis).

5 Increasing the dose of IL-12 profoundly reduced the IgG1 and IgG2b responses. The reduction in these immunoglobulin subclasses was not simply due to a change in the kinetics of the antibody response, as has been observed in the hen egg lysozyme (HEL) system (Buchanan, 10 Van Cleave and Metzger, Abstract #1945; 9th *International Congress of Immunology* (1995)), as these subclasses were reduced at all time points tested. The effect on IgG1 was expected given that switching of B cells to this subclass requires IL-4, a TH-2 cytokine 15 whose production is inhibited by IL-12. The reduction in IgG2b, however, was not expected since in previous studies increased levels of IgG2b have correlated with the presence of TH-1-like T cells. It is likely that cytokines other than, or in addition to, IFN- γ are 20 involved in regulation of IgG2b. For example, Germann et al. (*Eur J. Immunol* 25:823-829 (1995)) found that treating mice with anti-IFN- γ inhibited the ability of IL-12 to promote IgG2a responses, but not IgG2b. Other studies have implicated TGF- β as an important factor in 25 the induction of IgG2b (reviewed by J. Stavnezer, *J. Immunol.* 155:1647-1651 (1995)). Without wishing to be bound by theory, it is possible that high doses of IL-12 may affect TGF- β production or responsiveness to it.

30 IFN- γ is critical for the induction of IgG2a antibodies to T-dependent protein antigens (Finkelman

SUBSTITUTE SHEET (rule 26)

-12-

and Holmes, *Annu. Rev. Immunol.* 8:303-33 (1990)) and IgG3 responses to T-independent antigens (Snapper et al., *J. Exp. Med.* 175:1367-1371 (1992)). Increased IFN- γ response was consistently found after a single
5 vaccination with vaccine (PnPs-14-CRM₁₉₇) containing IL-12 and AlPO₄ and after boosting. The effect of IL-12 on the TH-2 cytokines IL-5 and IL-10 appears to depend on when the lymphoid cells are harvested after vaccination, and possibly on the particular cytokine. Exogenous IL-
10 12 completely abolished antigen-specific IL-5 and IL-10 production by lymph node cells (LNC) harvested 1 week after primary vaccination. After secondary vaccination, differences were seen between these two cytokines; IL-5 production by either LNC or splenocytes was completely
15 abolished by 1 μ g IL-12 in the vaccine, but IL-10 production was largely unaffected after boosting. It is unclear whether these differences are due to setting up the cultures at different times or reflect the expansion of a TH-2-like population upon subsequent revaccination.
20 The latter possibility is consistent with data from Wolf and colleagues (Bliss et al., *J. Immunol* 156:887-894 (1996)), indicating that IL-4-producing T cells can be recovered from Balb/c mice previously immunized with vaccine containing IL-12 and boosted with soluble
25 antigen. In their studies, IL-4 was detected even if IL-12 was included in the secondary vaccine. The presence of TH-2 cytokines after boosting may explain why, in Balb/c mice, even high levels of IL-12 could not reduce the secondary IgG1 response to below control
30 levels (conjugate vaccine on alum). Unlike the Balb/c

SUBSTITUTE SHEET (rule 26)

-13-

mice, high doses of IL-12 severely inhibited the IgG1 response of Swiss Webster mice. Whether this is associated with decreased production of TH-2 cytokines after the second vaccination is unclear.

5 In the present studies, IL-12 exhibited either only immunomodulatory activity or behaved both as a "classical" adjuvant, and a immunomodulator, depending on the vaccine. In the study with PnPs14-CRM₁₉₇, the IgG response (especially the primary response) to the
10 vaccine was not substantially elevated by the presence of the cytokine but certain subclasses, i.e. IgG2a and IgG3, were elevated whereas the others were unchanged or diminished. Thus, IL-12 is useful for altering the humoral response to an already immunogenic vaccine. It
15 is possible that in these studies the adjuvant activity of IL-12 was masked by the presence of alum, which is an adequate adjuvant on its own for the highly immunogenic PnPs-14 conjugate. The adjuvanticity of IL-12 may be better demonstrated in the absence of alum, by reducing
20 the dose of conjugate or by using a poorly immunogenic conjugate. Thus, further evaluations were carried out using IL-12 in the presence and absence of alum with PnPs6B conjugate vaccines, which are less immunogenic in Swiss Webster mice than PnPs-14 conjugate vaccines.

25 An additional study was designed to address the issue of IL-12 adjuvant activity for a poorly immunogenic pneumococcal conjugate. The Pn18C conjugate was chosen, as it is poorly immunogenic when formulated with AlPO₄, i.e., it induces low IgG titers and not all
30 mice respond to it. When formulated with MPL or QS-21,

SUBSTITUTE SHEET (rule 26)

-14-

higher IgG titers and a greater frequency of responders can be achieved.

One hundred µg MPL® plus AlPO₄ or 20 µg QS-21™ were the best adjuvants in this study for a Pn18C response as they induced the highest frequency of responders to this serotype. Nonetheless, IL-12 had marked effects on the IgG response to the carrier protein, CRM₁₉₇, in mice immunized with this conjugate. Moreover, the effects of the cytokine were modified by the presence of AlPO₄ in the vaccine. IL-12 clearly acted as an adjuvant for vaccines formulated without AlPO₄, causing a dose-dependent increase in IgG titers after primary and secondary vaccination. IL-12 enhanced the IgG2a response to CRM₁₉₇, which is consistent with its ability to favor the induction of TH-1-like helper cells (IFN-γ producers). However, IL-12 also enhanced the IgG1 response to CRM₁₉₇ after primary and secondary vaccination. IgG1 antibodies are normally associated with TH-2-like helper cells which produce IL-4.

Inclusion of 0.1 µg IL-12 into an AlPO₄-based Pn18C conjugate vaccine (which on its own induced a 10-fold higher CRM₁₉₇ response) had no effect on IgG1 but substantially increased the IgG2a titer. The IgG2a titer achieved with 0.1 µg IL-12 was at least as high as that obtained with 5 µg IL-12 in the absence of AlPO₄. It should be noted, however, that the presence of AlPO₄ does not preclude the enhancement of IgG1 responses by IL-12. In mice immunized with the Pn14 conjugate on AlPO₄, a 0.2 µg dose of IL-12 enhanced the IgG1, IgG2a and IgG2b titers to CRM₁₉₇. The differences in the

SUBSTITUTE SHEET (rule 26)

-15-

effect on IgG1 may reflect differences in the immunogenicity of the two conjugates for CRM₁₉₇ IgG responses; the Pn14 conjugate on AlPO₄ induced 10-fold lower CRM₁₉₇ IgG titers so that there was room for IL-12 to enhance an IgG1 response, but not when mice were immunized with Pn18C conjugate on AlPO₄. The fact that MPL® and QS-21™ markedly increased the IgG1 titers in mice immunized with Pn18C conjugate on AlPO₄ indicates that the IgG1 response had not been maximally stimulated. Alternatively, the nature of the saccharides on the conjugates may be a factor. In both experiments, higher doses of IL-12 resulted in a marked diminution of the IgG1, IgG2a and IgG2b titers to CRM₁₉₇, an effect that was not seen in the absence of AlPO₄.

IL-12 probably exerts its adjuvant effect differently than MPL® or QS-21™. IL-12 markedly enhanced the CRM₁₉₇ IgG2a titers in mice immunized with Pn18C conjugate but had minimal effects on IgG2b. In contrast, MPL® and QS-21™ enhanced the titers of both IgG subclasses. The dissociation of these two subclasses suggests that IgG2b is induced by cytokines other than, or in addition to, the IFN-γ that drives switching to IgG2a and is known to mediate the immunomodulatory effects of IL-12. One candidate for driving IgG2b production is TGFβ. The nature of the antigen cannot be excluded, however, since in mice immunized with Pn14 conjugate, 0.2 μg IL-12 caused IgG2a and IgG2b to be elevated to similar levels which were equivalent to the titers promoted by 25 μg MPL®.

SUBSTITUTE SHEET (rule 26)

-16-

Studies utilizing a bivalent vaccine consisting of a PnPs14-CRM₁₉₇ conjugate mixed with a conjugate of capsular polysaccharide from serotype 6B pneumococci covalently linked to CRM₁₉₇ (PnPs6B-CRM₁₉₇) confirmed and extended the above-described findings. IL-12 not only modified the IgG response to the Pn6B conjugate, but also enhanced the overall IgG titer to the conjugate. Moreover, this work further demonstrates that the adjuvant activity of relatively low doses of IL-12 is enhanced by formulating it with AlPO₄. Unlike the above-described studies with PnPs-14-CRM₁₉₇ glycoconjugate, IL-12/AlPO₄ enhanced both the IgG1 and IgG2a subclasses to Pn6B, indicating that the apparent lack of enhancement of the Pn14 IgG1 response by IL-12 is probably not a generalizable phenomenon. This work further supports the idea that the mechanisms of adjuvant activity by IL-12 and MPL® are not equivalent. Both adjuvants enhanced the Pn6B IgG1 and IgG2a titers to similar levels, but MPL® was more effective at promoting IgG2b and IgG3 antibodies.

IL-12/AlPO₄ did not act as an adjuvant for the Pn14 IgG response. The reason for this is not clear; however, without wishing to be bound by theory, this most likely reflects the fact that in previous studies mice were immunized with a 1 µg dose of PnPs-14-CRM₁₉₇ glycoconjugate, i.e., 10-fold higher than in the Pn6B studies. The applicability of IL-12 to more complex pneumococcal vaccines was demonstrated using a nonavalent vaccine containing glycoconjugates from serotype 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F

SUBSTITUTE SHEET (rule 26)

-17-

pneumococci. The combination of IL-12 with AlPO_4 enhanced the IgG2a antibodies to PnPs4 and PnPs9V, in addition to PnPs6B and PnPs14, and increased the ability of mice to respond to glycoconjugate prepared with serotype 18C pneumococcal saccharide (PnOs-18C-CRM₁₉₇) which is poorly immunogenic in mice.

In further examples, IL-12 was tested with a glycoconjugate vaccine against type C *Neisseria meningitidis* (MenC) and a glycoconjugate vaccine against type B *Hemophilus influenzae* (HbOC). Formulating that vaccine with 50 ng IL-12 and AlPO_4 enhanced the IgG2a titers to MenC capsular polysaccharide although not to HbOC.

The data presented herein indicate that AlPO_4 can greatly enhance the potency of IL-12 so that substantially lower doses of the cytokine can be used. One possible mechanism is that IL-12 binds to AlPO_4 , thereby enhancing its persistence in the animal; additional studies indicate that IL-12 rapidly binds to alum (data not shown). Alternatively, the local inflammatory effect of AlPO_4 may induce cytokines that potentiate the biological activity of IL-12.

In addition to understanding the physical interaction of IL-12 with AlPO_4 , several other issues arise from the present work with pneumococcal vaccines formulated with IL-12. Given that AlPO_4 enhances the activity of IL-12, it would be useful to know the minimal dose of cytokine needed to adjuvant the IgG response to pneumococcal glycoconjugates, as well as whether IL-5-producing T cells are activated by IL-12-

SUBSTITUTE SHEET (rule 26)

-18-

containing glycoconjugate vaccines. These two questions were addressed in the studies in Balb/c mice described in Example 4.

The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are hereby incorporated herein by reference.

EXAMPLES

EXAMPLE 1: Effect of IL-12 on the IgG response of Swiss Webster mice to serotype 14 pneumococcal capsular polysaccharide conjugated to CRM₁₉₇ on aluminum phosphate (PnPs-14-CRM/AlPO₄)

STUDY DESIGN

Swiss Webster mice (10 per group) were immunized twice (at weeks 0 and 3) with 1 µg PnPs-14-CRM₁₉₇ formulated with 100 µg AlPO₄ and either no IL-12, 0.2 µg, 1 µg or 5 µg IL-12. All vaccines included 0.25% normal mouse serum for the purpose of stabilizing the IL-12 when used at low concentrations. PnPs14-CRM₁₉₇ is a conjugate of capsular polysaccharide from serotype 14 pneumococci covalently linked to the genetically detoxified diphtheria toxin, CRM₁₉₇, by reductive amination. Another group received 25 µg MPL® (3-O-deacylated monophosphoryl lipid A, RIBI Immunochem Research, Inc., Hamilton Montana) instead of IL-12. The vaccinations were given subcutaneously three weeks

SUBSTITUTE SHEET (rule 26)

-19-

apart. Sera were collected at week 3 (primary response) and weeks 5 and 7 (secondary responses 2 and 4 weeks after boosting). The sera were analyzed for IgG antibodies to PnPs-14.

5 The sera were also analyzed for the ability to promote opsonophagocytic killing of type-14 pneumococci by human polymorphonuclear cells (PMN). Type 14 pneumococci were opsonized with dilutions of antisera and C8-depleted serum as a source of complement. They
10 were then incubated with human polymorphonuclear cells (PMN), and the percent of bacteria surviving was determined by colony counts.

RESULTS

 Table 1 shows that 1 μ g and 5 μ g IL-12
15 substantially reduced the anti-PnPs-14 IgG response in mice immunized with conjugate formulated with AlPO₄. The lowest dose (0.2 μ g) of cytokine had no effect on the total IgG response but caused major changes in the levels of the individual immunoglobulin subclasses. At
20 weeks 5 and 7 (2 and 4 weeks after boosting, respectively), 0.2 μ g IL-12 induced substantially higher IgG2a, IgG2b and IgG3 titers but left the IgG1 levels essentially unaltered. The IgG subclass profile induced
25 by 0.2 μ g IL-12 was indistinguishable from that obtained with 25 μ g MPL®, and sera from mice receiving these adjuvants had higher opsonophagocytic activity than those from mice immunized with a vaccine containing only AlPO₄ (Table 2).

SUBSTITUTE SHEET (rule 26)

-20-

The higher doses of IL-12 markedly reduced the IgG1 antibodies; at 5 μ g cytokine, IgG1 titers were at least 10-fold lower than in mice immunized without IL-12. This effect was apparent both during the primary
5 response and after boosting. Increasing the IL-12 dose did not cause further increases in IgG2a, IgG2b and IgG3, and, like IgG1, they also declined, although to varying degrees. IgG2b showed the greatest reduction such that vaccines containing 1 μ g or 5 μ g IL-12 induced
10 the same IgG2b titer as those without adjuvant. IgG2a and IgG3 were less sensitive to the effects of high IL-12 dose; even with 5 μ g IL-12, after the second vaccination these subclasses were higher than in the controls.

15 These studies showed that IL-12 could modulate the IgG subclass response to a PnPs14-CRM₁₉₇ conjugate vaccine formulated with AlPO₄. A 0.2 μ g dose of IL-12 increased the IgG2a, IgG2b and IgG3 response to Pn14 without affecting the IgG1 response. Higher doses of
20 IL-12 resulted in a marked reduction in the IgG1 and IgG2b titers. IgG2a and IgG3 titers also appeared to decline at these doses, but they were still higher than in mice immunized in the absence of IL-12. Example 2 demonstrates that the IgG subclass changes were
25 associated with enhanced induction of IFN- γ -producing, CRM₁₉₇-specific T cells and a marked reduction in antigen-specific IL-5 production, suggesting a change in the T helper cell phenotype from TH-2-like to TH-1-like.

SUBSTITUTE SHEET (rule 26)

-21-

Table 1: Effect of IL-12 on the immunogenicity of PnPs-14-CRM₁₉₇/alum vaccine

Time	Adjuvant	Dose (μ g)	PnPs14 IgG Response				
			IgG	IgG1	IgG2a	IgG2b	IgG3
week 3	None		56,035	8,394	481	298	1,312
	IL-12	5	13,137	480	2,417	388	2,398
	IL-12	1	26,131	1,521	3,249	736	3,858
	IL-12	0.2	90,220	13,779	4,731	1,454	7,944
	MPL®	25	46,451	14,303	1,506	8,506	18,203
week 5	None		531,270	189,571	5,507	14,463	18,158
	IL-12	5	231,015	16,900	28,719	6,002	56,982
	IL-12	1	198,044	36,327	27,420	11,841	30,740
	IL-12	0.2	722,360	305,623	60,701	89,397	99,794
	MPL®	25	751,066	221,324	44,957	91,265	77,989
week 7	None		694,741	244,212	1,801	6,849	9,245
	IL-12	5	177,438	17,232	20,276	3,494	26,859
	IL-12	1	183,571	44,213	21,246	5,063	13,447
	IL-12	0.2	852,292	251,157	37,104	37,717	88,933
	MPL®	25	783,622	187,055	30,694	89,153	59,297

SUBSTITUTE SHEET (rule 26)

-22-

Table 2: Opsonophagocytic activity of sera of mice immunized with PnPs-14-CRM₁₉₇/AlPO₄ formulated with IL-12 or MPL®

Initial Serum Dilution Tested	% Bacteria Surviving									
	Week 5 Sera					Week 7 Sera				
	No IL-12	0.2 µg IL-12	1 µg IL-12	5 µg IL-12	25 µg MPL®	No IL-12	0.2 µg IL-12	1 µg IL-12	5 µg IL-12	25 µg MPL®
2	6	10	6	6	9	6	6	7	7	5
8	12	7	9	9	7	21	4	10	9	6
16	32	4	24	25	3	47	8	17	26	8
32	71	12	61	94	23	68	6	85	90	21
64	64	46	90	89	51	116	34	79	99	76

SUBSTITUTE SHEET (rule 26)

-23-

EXAMPLE 2: Nature of T helper cells induced by
Pneumococcal conjugate vaccine (PnPs-14-
CRM₁₉₇/AlPO₄) formulated with IL-12

STUDY DESIGN

5 Groups of eight (8) Balb/c mice were immunized
subcutaneously at the base of the tail with 1 μ g PnPs-
14-CRM₁₉₇ conjugate formulated with 100 μ g AlPO₄ and
different doses of IL-12. Normal mouse serum (0.25%)
was included as a carrier protein. One week later,
10 draining lymph node cell suspensions were prepared from
half the mice in each group and cultured with CRM₁₉₇,
lysozyme, ConA or in medium alone for 6 days. Culture
supernatants from parallel cultures were harvested at
day 3 and day 6 and assayed for IFN- γ , IL-5 and IL-10 by
15 ELISA.

At three weeks, the remaining mice were bled and
reimmunized with the same vaccine formulation used in
the first immunization. Fourteen days after the second
immunization (week 5), the mice were bled once more.
20 Four days later their draining lymph node cells and
splenocytes were harvested and cultured for six days
with CRM₁₉₇, lysozyme, ConA or in medium alone. Culture
supernatants from parallel cultures were harvested at
day 3 and day 6 and assayed for IFN- γ , IL-5 and IL-10 by
25 ELISA.

RESULTS

Formulating PnPs-14-CRM₁₉₇/AlPO₄ vaccine with the
lower doses of IL-12 (0.2 μ g and 1.0 μ g) greatly

SUBSTITUTE SHEET (rule 26)

-24-

enhanced the IgG2a and IgG3 responses to Pn14 at week 5, but not IgG1 (see Table 3). Several differences were seen between the results obtained with Balb/c mice and Swiss Webster mice in the previous experiment; in this experiment IL-12 did not dramatically increase the IgG2b antibodies to Pn14, nor did the 5 μ g IL-12 dose cause the dramatic (> 10-fold) reduction in IgG1 titers relative to the control group without cytokine.

One week after immunization, lymph node cells from mice immunized without IL-12 produced IFN- γ , IL-5 and IL-10 when stimulated with CRM₁₉₇ *in vitro* (Table 4). Adding IL-12 to the vaccine dramatically increased the antigen-specific production of IFN- γ and abolished the ability of the lymphoid cells to produce IL-5 and IL-10. Maximal IFN- γ production was obtained with the lowest dose of IL-12 (0.2 μ g); higher doses, particularly 5 μ g, appeared to reduce the levels of this cytokine. This was most clearly seen in cultures stimulated with 1 μ g/mL CRM₁₉₇. The reduction in IFN- γ with higher doses of IL-12 may not reflect a generalized suppressive phenomenon since IFN- γ production in response to Con A was the same regardless of the dose of IL-12 in the vaccine.

Two weeks after the second immunization, lymph node cells and splenocytes from mice immunized with vaccine containing IL-12 continued to produce elevated levels of IFN- γ in response to stimulation with CRM₁₉₇ compared to mice immunized without IL-12 (Table 5). As observed 7 days after primary vaccination, 0.2 μ g to 1.0 μ g IL-12 were optimal doses of IL-12 for augmentation of an IFN- γ response. In contrast, however, IL-5 and IL-10

SUBSTITUTE SHEET (rule 26)

-25-

production were differentially affected. The 1.0 and
5.0 μg doses of IL-12 essentially eliminated the IL-5
response but, by comparison, had only a minor effect on
IL-10 production. IL-12 (5.0 μg) abolished the ability
5 of splenocytes but not lymph node cells to produce IL-10
(Tables 5 and 6).

-26-

Table 3: Effect of IL-12 on immune response to an alum-based PnPs14 glycoconjugate vaccine in Balb/c Mice

Week	IL-12 Dose	IgG	IgG1	IgG2a	IgG2b	IgG3
3	none	41,480	7,347	1,387	895	2,333
	0.2	26,253	1,521	1,118	171	5,911
	1	26,124	966	2,155	248	5,991
	5	10,753	541	671	183	3,242
5	none	234,220	33,284	2,896	3,105	2,487
	0.2	674,996	71,808	18,245	6,789	107,470
	1	632,714	32,022	22,749	7,853	44,350
	5	224,832	19,495	10,083	1,287	25,212

-27-

Table 4: Cytokines produced by lymph node cells taken 7 days after single immunization with PnPs-14 conjugate formulated with AlPO₄ and IL-12

			Day 6 Cultures			
Cytokine	Antigen in vitro $\mu\text{g/ml}$		No IL-12	0.2 μg IL-12	1.0 μg IL-12	5.0 μg IL-12
IFN- γ (U/mL)	CRM	30	23.2	102.7	60.5	32.2
	CRM	1	<0.75	65.2	28.6	8.7
	Lysozyme	30	<0.75	2.9	6.6	4.5
	Con A	1	43.8	97.1	107.1	105.4
	Medium	-	<0.75	3.6	10.6	5.2
IL-5 (ng/mL)	CRM	30	7.2	<0.22	<0.22	<0.22
	CRM	1	2.2	<0.22	<0.22	<0.22
	Lysozyme	30	<0.22	<0.22	<0.22	<0.22
	Con A	1	<0.22	<0.22	<0.22	<0.22
	Medium	-	<0.22	<0.22	<0.22	<0.22
IL-10 (ng/mL)	CRM	30	10.4	0.8	0.21	0.21
	CRM	1	2.6	0.21	0.21	0.21
	Lysozyme	30	<0.14	0.21	0.21	0.21
	Con A	1	<0.14	0.21	0.21	0.21
	Medium	-	<0.14	0.21	0.21	0.21

SUBSTITUTE SHEET (rule 26)

-28-

Table 5: Cytokine production by splenocytes two weeks after secondary vaccination with PnPs-14 conjugate formulated with AlPO₄ and IL-12

			Day 6 Cultures			
Cytokine	Antigen in vitro	$\mu\text{g/ml}$	No IL-12	0.2 μg IL-12	1.0 μg IL-12	5.0 μg IL-12
IFN- γ (U/mL)	CRM	30	7.0	98.4	83.2	50.9
	CRM	1	1.0	89.2	76.8	16.4
	Lysozyme	30	<0.4	<0.4	<0.3	<0.3
	Con A	1	42.7	48.7	50.6	49.5
IL-5 (ng/mL)	CRM	30	13.2	3.1	0.6	<0.2
	CRM	1	4.5	4.4	0.8	<0.2
	Lysozyme	30	<0.3	<0.3	<0.2	<0.2
	Con A	1	<0.3	<0.3	<0.2	<0.2
IL-10 (ng/mL)	CRM	30	8.6	4	7.1	0.6
	CRM	1	1.1	2.5	1.7	<0.2
	Lysozyme	30	<0.2	<0.2	<0.3	<0.2
	Con A	1	0.5	0.4	<0.3	<0.2

SUBSTITUTE SHEET (rule 26)

-29-

Table 6: Cytokine production by lymph node cells two weeks after secondary vaccination with PnPs-14 conjugate formulated with AlPO₄ and IL-12

Cytokine	Antigen <i>in vitro</i>	pg/ml	Day 6 Cultures			
			No IL-12	0.2 µg IL-12	1.0 µg IL-12	5.0 µg IL-12
IFN-γ (U/mL)	CRM	30	9.8	86.9	58.7	62.0
	CRM	1	0.6	78.6	62.9	36.8
	Lysozyme	30	<0.4	<0.4	<0.3	<0.3
	Con A	1	17.7	57.6	45.7	69.0
IL-5 (ng/mL)	CRM	30	12.5	1.4	<0.2	0.5
	CRM	1	4.8	2.2	<0.2	<0.2
	Lysozyme	30	<0.3	<0.3	<0.2	<0.2
	Con A	1	1.1	<0.3	<0.2	<0.2
IL-10 (ng/mL)	CRM	30	11.3	9.9	7.2	3.6
	CRM	1	4.4	5.5	3.3	1
	Lysozyme	30	<0.2	<0.2	<0.2	<0.2
	Con A	1	<0.2	<0.2	<0.2	<0.2

SUBSTITUTE SHEET (rule 26)

-30-

EXAMPLE 3: IL-12 adjuvant activity with poorly
immunogenic Pneumococcal conjugate

Study Design

Swiss-Webster mice (10 per group) were immunized
5 with 1 µg Pn18C conjugate formulated with or without 100
µg AlPO₄. The vaccines were supplemented with either IL-
12 (0.2, 1 or 5 µg), 100 µg MPL® or 20 µg QS-21™.
Normal mouse serum (0.5% final) was used to stabilize
the diluted IL-12 and was added to all vaccines,
10 regardless of composition. Three weeks later, the mice
were bled and boosted with the same vaccine formulation
used at the primary immunization. Bleeds were also
taken at weeks 5 and 7 of the study (2 and 4 weeks after
boosting, respectively). Pooled sera were tested at
15 week 5 for Pn18C and CRM₁₉₇ total IgG and IgG subclasses.
To determine the frequency of responders to Pn18C, the
sera for individual mice were diluted 1/500 and tested
by ELISA for IgG antibodies to Pn18C. Results are
reported as optical density.

20 Results

The Pn18C IgG responses are presented in Table 7.
The addition of IL-12 to alum-formulated conjugate
vaccine had no consistent effect on the IgG response to
Pn18C. A dose of 5 µg of IL-12 caused a 3-fold rise in
25 the IgG titer of pooled week 5 sera, whereas vaccine
formulated with 1 µg of IL-12 appeared to induce no

SUBSTITUTE SHEET (rule 26)

-31-

Pn18C response. The lowest dose of IL-12 (0.1 µg) induced the same response as the AlPO₄-formulated vaccine not containing IL-12. The vaccine formulated with MPL®/AlPO₄ induced the highest frequency of responses; 7/10 mice gave OD>0.2, in contrast to QS-21™/AlPO₄ and AlPO₄ alone, each of which induced 4/10 responders. Mice immunized with vaccine containing IL-12 plus AlPO₄ induced 2/10, 0/10 and 1/10 responders at IL-12 doses of 0.1 µg, 1.0 µg, and 5 µg, respectively.

In this experiment MPL® and QS-21™ caused at most a 3- to 4-fold increase in the Pn18C IgG response. In the absence of AlPO₄, IL-12 did not have a profound adjuvant effect on the Pn18C IgG response. The vaccine containing a 1 µg dose of IL-12 induced the same Pn18C response as vaccine without IL-12. Vaccines containing the lower and higher doses of IL-12 appeared to induce lower responses than the control vaccine. Neither MPL® nor QS-21™ appeared to enhance the Pn18C IgG response. Among the vaccines formulated without AlPO₄, QS-21™ induced the highest frequency of responders (7/10 with OD>0.2), whereas all other formulations induced 4/10 responders, at most.

To confirm that the IL-12 in the vaccine was indeed active, the CRM₁₉₇ IgG response in these mice was evaluated. Tables 8 and 9 show that after primary (week 3) and secondary (week 5) vaccination, IL-12 causes a dose-dependent increase in CRM₁₉₇ IgG response in mice immunized with vaccine formulated without AlPO₄. Moreover, there was an IL-12 dose-dependent increase in both IgG1 and IgG2a titers at weeks 3 and 5, as well as

SUBSTITUTE SHEET (rule 26)

-32-

an increase in IgG2b at week 5. The IgG1 and IgG2a titers at week 5 were similar to those induced by vaccine formulated with 100 µg MPL®. In contrast, the IgG2b titers promoted by IL-12 were 20-fold lower than those induced by MPL®. These data suggest that IgG2a and IgG2b are controlled by different mechanisms, IgG2a being dependent on a mechanism activated by IL-12 and IgG2b being controlled by an IL-12-independent mechanism. These data clearly indicate that IL-12 can act as adjuvant for IgG responses to a protein antigen. Moreover the increase in both IgG1 and IgG2a titers suggest that, within this model at least, IL-12 enhances priming of both TH-1-like and TH-2-like helper cells by PnOs18C-CRM₁₉₇ conjugate in the absence of AlPO₄.

When added to the Pn18C conjugate vaccine formulated with AlPO₄, the 0.1 µg dose of IL-12 caused little if any increase in the week 3 total IgG response to CRM₁₉₇, but a 3-fold increase at week 5. However, this dose of IL-12 increased the IgG2a titer at week 5, promoting titers similar to that induced by vaccine containing MPL or QS-21. IL-12 did not markedly increase the IgG2b titers. As seen in previous experiments, higher doses of IL-12 resulted in a sharp decline in IgG titers with all subclasses being affected.

SUBSTITUTE SHEET (rule 26)

ACC96-03p

-33-

Table 7: Effect of IL-12 on IgG response to PhOsl8C conjugate

	Adjuvant ($\mu\text{g}/\text{dose}$)	IgG titer		IgG subclasses at Week 5			
		Wk3	Wk5	IgG1	IgG2a	IgG2b	IgG3
5	AlPO ₂	<100	4,608	4,591	116	<100	<100
	0.1 μg IL-12 + AlPO ₄	<100	3,681	1,472	265	259	450
	1.0 μg IL-12 + AlPO ₄	<100	130	<100	<100	<100	<100
	5.0 μg IL-12 + AlPO ₄	260	13,545	7,820	1,426	<100	1,481
	100 μg MPL/AlPO ₄	233	9,027	1,522	935	877	<100
	QS-21 + AlPO ₄	<100	7,989	879	1,395	1,062	1,004
10	none	107	10,768	5,238	345	<100	144
	0.1 μg IL-12	<100	1,808	336	105	<100	<100
	1.0 μg IL-12	<100	22,257	12,443	671	172	773
	5.0 μg IL-12	<100	460	203	<100	<100	400
	100 μg MPL	112	1,729	524	363	189	126
15	QS-21	<100	3,573	2,483	101	<100	113

ACC96-03p

-34-

Table 8: Effect of IL-12 on CRM₁₉₇ IgG response three weeks after vaccination with PnOs18C conjugate

	Adjuvant (µg/dose)	IgG	IgG1	IgG2a
5	AlPO ₄	70,964	8,706	3,516
	0.1 µg IL-12 + AlPO ₄	103,589	4,754	13,025
	1.0 µg IL-12 + AlPO ₄	26,927	506	2,926
	5.0 µg IL-12 + AlPO ₄	19,579	241	2,665
	100 µg MPL®/AlPO ₄	651,315	92,245	79,508
10	QS-21™/AlPO ₄	572,255	116,583	38,419
	None	7,630	452	1,023
	0.1 µg IL-12	32,403	3,475	3,713
	1.0 µg IL-12	60,987	4,615	5,951
	5.0 µg IL-12	128,697	10,498	10,686
15	100 µg MPL®/TEM	462,289	40,010	24,979
	QS-21™	556,440	111,533	53,799

SUBSTITUTE SHEET (rule 26)

ACC96-03p

-35-

Table 9: Effect of IL-12 on CRM197 IgG response five weeks after vaccination with PnOs18C conjugate (two weeks after boosting)

	Adjuvant ($\mu\text{g}/\text{dose}$)	IgG	IgG1	IgG2a	IgG2b
5	AlPO ₄	634,631	102,974	45,955	8,812
	0.1 μg IL-12 + AlPO ₄	2,225,000	88,204	317,083	16,869
	1.0 μg IL-12 + AlPO ₄	105,765	8,018	12,598	1,096
	5.0 μg IL-12 + AlPO ₄	71,618	1,582	13,806	744
	100 μg MPL®/AlPO ₄	4,384,000	637,655	371,652	111,646
10	QS-21™/AlPO ₄	>5,000,000	>1,000,000	873,674	144,132
	None	62,341	12,783	3,655	1,679
	0.1 μg IL-12	296,791	52,288	23,741	7,069
	1.0 μg IL-12	1,026,060	101,381	96,024	11,862
	5.0 μg IL-12	1,367,771	74,494	108,815	14,258
15	100 μg MPL®/TEM	4,173,765	264,691	266,160	303,662
	QS-21™	>5,000,000	1,303,508	445,712	131,991

-36-

EXAMPLE 4: Effect of IL-12 on the IgG response of Swiss Webster mice to bivalent vaccine containing PnPs6B-CRM₁₉₇ and PnPs-14-CRM₁₉₇

STUDY DESIGN

5 Swiss Webster mice were immunized subcutaneously at weeks 0 and 3 with a vaccine comprising 0.1 µg per dose of PnPs6B-CRM₁₉₇ glycoconjugate (a conjugate of capsular polysaccharide from serotype 6B pneumococci covalently linked to CRM₁₉₇) plus 0.1 µg per dose of PnPs14-CRM₁₉₇ glycoconjugate. The vaccines were administered with 0, 10 8, 40, or 200 ng IL-12, either alone or in combination with 100 µg alum (AlPO₄). Normal mouse serum (0.25%) was included as a carrier protein to stabilize the IL-12 at low concentrations. A control group of mice was 15 immunized with the vaccine formulated with 100 µg monophosphoryl lipid A (MPL®). The mice were bled at week 3 (primary response) and week 5 (secondary response). Sera were tested for IgG antibodies to Pn6B and Pn14 capsular polysaccharide by ELISA.

20 RESULTS

Response to PnPs6B conjugate

Table 10 illustrates the pooled serum IgG response to the Pn6B component of the bivalent vaccine. Little or no response to Pn6B was detected at week 3 if the vaccine 25 contained no adjuvant or was formulated with only AlPO₄. The highest titers after a single vaccination appeared to

SUBSTITUTE SHEET (rule 26)

-37-

be induced by vaccine containing either MPL® or 8-40 ng of IL-12 co-formulated with alum. These titers however were low, i.e., less than 3,000. The week 5 responses show that after boosting, vaccines formulated with 40 ng IL-12 plus AlPO₄ or with MPL® induced the highest IgG titers to Pn6B. In the absence of alum, IL-12 in the 8 to 200 ng dose range did not enhance the IgG titers to Pn6B.

The IgG subclass response to Pn6B at week 5 is shown in Table 10. The titers of the individual IgG subclasses were similar in mice immunized with vaccine containing no adjuvant or vaccine formulated with AlPO₄ (no IL-12). Moreover, formulating the vaccines with 8-200 ng of IL-12 in the absence of AlPO₄ did not alter the IgG subclass response. In contrast, these doses of IL-12 when combined with AlPO₄ resulted in substantially increased IgG1 and IgG2a titers to Pn6B. These titers were similar to those obtained with vaccine formulated with MPL®. IL-12 also increased the IgG2b and IgG3 titers induced by vaccine formulated with AlPO₄; however, these titers appeared to be substantially lower than those induced by vaccine formulated with MPL®.

To determine if the increases obtained with a combination of IL-12 and AlPO₄ were statistically significant, the Pn6B IgG titers of individual mice in selected groups were determined. The geometric mean titers (GMT) are presented in Table 11. The data indicate that groups immunized with vaccines formulated without adjuvant or with AlPO₄ alone had similar GMT against Pn6B. Formulating the vaccine with AlPO₄ plus

SUBSTITUTE SHEET (rule 26)

-38-

40ng IL-12 resulted in a 29-fold increase in titer over that induced by vaccine containing no adjuvant. When all the data were tested by ANOVA (analysis of variance by JMP software; SAS Institute, Cary, North Carolina), no statistically significant differences were found. Upon comparison of subsets of data, ANOVA indicated a statistically significant difference when comparing the week 5 responses induced by vaccine containing no adjuvant and vaccines formulated with AlPO₄ and various doses of IL-12. Of these, the vaccine formulated with AlPO₄ plus 40 ng IL-12 induced a significantly higher Pn6B titer than vaccine formulated without adjuvant. As a further indication of the heightened immunogenicity of that formulation, 7 of the 10 mice in that group had Pn6B titers greater than or equal to 50,000 compared to only 1 and 2 mice each in the groups vaccinated with conjugate formulated without adjuvant or with AlPO₄ alone.

SUBSTITUTE SHEET (rule 26)

ACC96-03p

-39-

Table 10: Effect of IL-12 on the IgG response to PnPs6B in mice immunized with a bivalent PnPs6B/14 pneumococcal glycoconjugate vaccine

Group	Adjuvant	Pn6B IgG Titer*			Pn6B IgG Subclass Response at Week 5*				
		Week 3	Week 5	IgG1	IgG2a	IgG2b	IgG3		
P344	200 ng IL-12 +	630	161,867	19,474	22,664	2,954	7,333		
P345	40 ng IL-12 +	2,609	429,006	61,364	24,172	4,117	9,830		
P346	8 ng IL-12 + AlPO ₄	1,977	284,206	46,734	32,859	3,195	8,764		
P347	AlPO ₄ (no IL-12)	279	120,999	8,767	2,199	688	301		
P348	200 ng IL-12	<100	22,401	6,816	3,147	501	1,104		
P349	40 ng IL-12	164	23,343	5,056	2,532	879	292		
P350	8 ng IL-12	642	81,748	17,702	3,573	5,151	1,786		
P351	None	<100	20,153	3,061	1,506	364	1,220		
P352	100 µg MPL®	2,872	840,513	84,660	30,813	43,505	25,749		

* Pooled serum titers

Table 11: Pn6B IgG titers of individual mice

Group	P344	P345	P346	P347	P350	P351	P352
Mouse #	AlPO ₄ + 200 ng IL-12	AlPO ₄ + 40 ng IL-12	AlPO ₄ + 8 ng IL-12	AlPO ₄ (no IL-12)	8 ng IL-12	No Adjuvant	100 µg MPL®
1	1,957	596,886	13,457	306,012	833,148	3,544	7,556
2	2,498	1,205	1,000,000	3,653	9,431	326	1,359,470
3	100	9,453	1,422	8,708	3,163	1,136	81
4	11,830	70,278	168,481	41,395	109,399	24,140	583,097
5	1,823	157,427	16,454	677,407	252	50,785	86,656
6	6,114	90,843	989	9,089	150,245	228	284
7	279	49,182	372,709	17,164	112	1,351	1,000,000
8	756,503	408,348	425	7,329	393	36,805	473,652
9	1,000,000	1,000,000	667,988	100	13,622	22,817	927,213
10	177	1,052,210	6,206	245	182,629	851	—
GMT	4,347	103,743	22,580	9,735	10,120	3,589	55,799
Mice with titer ≥50,000	2	7	4	2	4	1	6

Statistical Comparisons (ANOVA: $\alpha=0.05$)AlPO₄ + 40 ng IL-12 vs. no adjuvant: significant

-41-

Response to PnPs14 conjugate

The IgG response to the PnPs14 component of the vaccine is shown in Table 12. The data indicate that IL-12 in the 8-40 ng dose range, either alone or when formulated with AlPO₄, did not enhance the response to PnPs14 after primary or secondary vaccination. Moreover, subclass analysis indicated that IL-12 did not enhance the IgG2a titers when formulated with IL-12. In this study, MPL® did not have the profound adjuvant effect on the PnPs14 response that was observed in previous studies, at least when assaying pooled sera. To get an idea of the degree of variation of the response of each group, individual sera were assayed for Pn14 IgG antibodies at a 1/300 dilution. The results presented in Table 13 suggest that there was a large range of responses in each group, i.e., the Coefficient of Variation (CV) ranged from 0.229 to 0.587, with the exception of the group immunized with vaccine containing MPL® where the CV was 0.051. Thus, it appeared that MPL®, but not IL-12, may have acted as an adjuvant for the Pn14 IgG response and reduced the mouse-to-mouse variation.

Table 12: Effect of IL-12 on the IgG subclass response to Pn14 in mice immunized with a bivalent PnPs6B/14 pneumococcal glycoconjugate vaccine

Adjuvant	PnPs14 Ig* Titer*		PnPs14 IgG Subclass at Week 5*			
	Week 3	Week 5	IgG1	IgG2a	IgG2b	IgG3
200 ng IL-12 + AlPO ₄	2,170	58,657	6,880	8,996	1,945	5,995
40 ng IL-12 + AlPO ₄	1,641	53,557	8,646	3,003	3,684	2,745
8 ng IL-12 + AlPO ₄	2,181	85,173	10,094	11,346	5,328	2,560
AlPO ₄ (no IL-12)	2,102	201,082	54,989	4,030	6,402	3,745
200 ng IL-12	849	18,293	5,769	1,582	536	799
40 ng IL-12	1,544	11,442	4,350	714	514	455
8 ng IL-12	113	12,169	5,286	354	245	330
None	509	22,601	6,080	808	618	694
100 µg MPL®	18,616	77,106	15,745	4,275	10,205	3,916

*Pooled serum titers

SUBSTITUTE SHEET (rule 26)

Table 13: Response of individual mice to Pn14 component of Pn6B/Pn14 bivalent pneumococcal conjugate vaccine*

Adjuvant	O.D. Range	O.D. Mean	Standard Deviation	Coefficient of Variation
AlPO ₄ + 200 ng IL-12	0.034-0.990	0.788	0.318	0.404
AlPO ₄ + 40 ng IL-12	0.457-0.948	0.771	0.176	0.229
AlPO ₄ + 8 ng IL-12	0.023-0.923	0.707	0.281	0.397
AlPO ₄ (no IL-12)	0.328-0.974	0.770	0.220	0.285
8 ng IL-12 (no alum)	0.009-0.812	0.505	0.292	0.587
No adjuvant	0.030-0.876	0.614	0.343	0.558
100 µg MPL®	0.791-0.918	0.863	0.044	0.051

*Individual sera tested by ELISA at 1/300 dilution for IgG antibodies to Pn14.

-44-

EXAMPLE 5: Comparison of the effect of IL-12 in the presence or absence of alum on the murine immune response to monovalent PnPs14-CRM₁₉₇ conjugate vaccine

5 STUDY DESIGN

BALB/c mice (8 per group) were immunized subcutaneously at week 0 with 1 µg PnPs14-CRM₁₉₇ conjugate formulated with or without 100 µg AlPO₄ and either no IL-12 or with 8, 40, 200, 1,000 or 5,000 ng IL-12. Normal mouse serum (0.25%) was included as a carrier protein to stabilize IL-12 at low concentrations. At week 1, lymph node cell suspensions were prepared from half the mice in each group and evaluated for antigen-specific cytokine production in vitro. Their spleens were also harvested and weighed. At week 3 the remaining mice were bled and re-immunized with the same vaccine formulation used in the initial vaccination. At week 5 the twice-immunized mice were bled, their spleens weighed and their splenocytes evaluated for cytokine production. PnPs14 and CRM₁₉₇ IgG and IgG subclass titers were determined on pooled sera. When the assays were performed using sera from individual mice, the results are expressed as geometric mean titers (GMT).

25 RESULTS

Effect of IL-12 on spleen weight one week after immunization

SUBSTITUTE SHEET (rule 26)

-45-

One week after the first immunization, mice receiving 5,000 ng IL-12, but not lower doses of IL-12, in the absence of AlPO_4 , had significantly higher spleen weights than those receiving vaccine containing neither alum nor IL-12 (Table 14). Vaccines containing AlPO_4 induced higher spleen weights when formulated with 40 to 5000 ng IL-12. Pair-wise comparisons indicated that vaccines formulated with 200 or 1000 ng IL-12 plus AlPO_4 induced higher spleen weights than those formulated with the same dose of IL-12 in the absence of AlPO_4 . Overall, the data indicate that formulating IL-12 with AlPO_4 greatly enhanced a biological activity of the cytokine, i.e., its ability to cause increased spleen weight one week after vaccination.

Effect of IL-12 on the IgG response to PnPs14

Initially, pooled sera were assayed for IgG antibodies to PnPs14 (Table 15). The clearest indication of an adjuvant effect was noted after primary immunization with vaccine containing AlPO_4 and 8 to 40 ng IL-12. This combination resulted in a 17- to 21-fold increase in the IgG titer relative to mice immunized with vaccine formulated with neither AlPO_4 nor IL-12. The combination of AlPO_4 and IL-12 resulted in higher responses than when used individually; on their own AlPO_4 and the 40 ng dose of IL-12 caused 4-fold and 5-fold increase in week 3 IgG titers, respectively. Analysis of individual sera from mice immunized with AlPO_4 -containing vaccines (Table 16) showed that 8 ng IL-12 induced 5-fold higher PnPs14 IgG titer after primary vaccination than vaccine adjuvanted with only AlPO_4 . The

SUBSTITUTE SHEET (rule 26)

-46-

difference in titers was statistically significant. Higher doses of IL-12 did not enhance the response. The 1,000 to 5,000 ng doses of IL-12 caused a marked decline in PnPs14 IgG titers. After the second immunization only the 40 ng dose of IL-12 caused a significant rise (3-fold) in the PnPs14 titer induced by the AlPO₄-based vaccine.

The pooled serum data suggest that the combination of AlPO₄ and 8-40 ng IL-12 enhanced the IgG1 titers after primary immunization. After two vaccinations, IL-12 did not enhance the IgG1 titers to PnPs14 in mice immunized with conjugate in the absence of AlPO₄ as indicated by analysis of pooled (Table 15) and individual sera (Table 17). Moreover, among mice immunized with vaccine containing AlPO₄, the addition of 8 to 200 ng IL-12 did not result in higher IgG1 titers after 2 vaccinations (Table 17).

The most profound effect of IL-12 was to substantially increase the PnPs14 IgG2a response at week 5. This was seen both when the vaccine contained AlPO₄ or was formulated without AlPO₄ (Table 18). In the absence of AlPO₄, statistically significant increases (14- to 42-fold) in IgG2a GMT were obtained with 8 to 1,000 ng IL-12. Similarly, 8-1,000 ng IL-12 enhanced the ability of AlPO₄-containing vaccines to induce IgG2a antibodies, although in this study only the titers induced by the 8 and 40 ng doses of IL-12 were statistically higher. Overall, the highest IgG2a titers were induced by conjugate formulated with AlPO₄ and 40 ng IL-12. This was significantly different from the IgG2a

SUBSTITUTE SHEET (rule 26)

-47-

titers induced by 40 ng IL-12 in the absence of AlPO_4 , again indicating that the adjuvant activity of IL-12 was enhanced by alum.

5 IgG2b and IgG3 titers were assayed on pooled sera only (Table 15). Doses of IL-12 in the range of 8 to 1,000 ng when co-formulated with AlPO_4 , but not in its absence, promoted substantial increases in IgG3 titers after primary and secondary immunization. No consistent effect of IL-12 on the IgG2b titers was noted.

10 Effect of IL-12 on the IgG response to CRM₁₉₇

The IgG response to CRM₁₉₇ was also evaluated to see if there were differences between the effect of IL-12 on the protein carrier versus the polysaccharide portion of the conjugate (Table 19). In the absence of AlPO_4 , 40 ng
15 IL-12 appeared to modestly increase the IgG titers to CRM₁₉₇ after two vaccinations. However, the highest IgG titers to CRM₁₉₇ were obtained when the vaccine was formulated with both AlPO_4 and 8-40 ng IL-12. The heightened adjuvant activity of IL-12 co-formulated with
20 AlPO_4 is indicated by the finding that, on their own, 40 ng IL-12 and AlPO_4 resulted in 6-fold and 17-fold increases in IgG titer at week 5, but when combined together the increase was 147-fold. IL-12 enhanced the IgG1 response to CRM₁₉₇, regardless of whether the vaccine
25 was formulated with or without AlPO_4 (Tables 19 and 20). IL-12 substantially increased the week 5 IgG2a titers to CRM₁₉₇ after immunization with vaccines containing AlPO_4 (Table 19). Again the optimal dose of IL-12 appeared to

SUBSTITUTE SHEET (rule 26)

-48-

be 40 ng. The cytokine appeared to increase the IgG2b titers induced by vaccine containing AlPO_4 .

Effect of IL-12 on cytokine profile of CRM₁₉₇-specific T cells

5 Cytokine production by spleen cells taken two weeks after secondary vaccination (week 5) revealed effects of IL-12 on the priming of both IFN- γ and IL-5 producing cells. Splenocytes from mice immunized in the absence of AlPO_4 and IL-12 produced detectable levels of IL-5, 10 but not IFN- γ , when stimulated with CRM₁₉₇, *in vitro* (Table 21). Formulating the vaccine with IL-12 appeared to enhance the induction of IL-5-producing cells with peak activity occurring with 40 ng of the cytokine. Higher doses of IL-12 resulted in decreased production 15 of IL-5, with virtually no cytokine being produced by mice immunized with conjugate vaccine containing 1,000 to 5,000 ng IL-12. Convincing IFN- γ production was detected only from the splenocytes of mice immunized with vaccines formulated with 5,000 ng IL-12. When the 20 vaccine was formulated with AlPO_4 , the addition of 8 ng IL-12 resulted in priming of cells that produced copious amounts of IFN- γ , whereas in the absence of the cytokine only antigen-specific IL-5 production was detected. It appears that priming for maximal IFN- γ production occurs 25 with 40 to 1,000 ng IL-12. Addition of 5,000 ng IL-12 abolished the ability of the vaccine to prime for IL-5-producing cells.

Table 14: Spleen weights of Balb/c mice one week after subcutaneous immunization with 1 μ g PnPs14-CRM₁₉₇ conjugate formulated with or without 100 μ g AlPO₄ and the indicated doses of IL-12

Group Code	Adjuvant Formulation		Spleen Weight (grams)	
	IL-12 (ng)	AlPO ₄	AVERAGE	Standard Deviation
P641	0	-	0.179	0.0225
P642	8	-	0.148	0.0112
P643	40	-	0.162	0.0202
P644	200	-	0.175	0.0431
P645	1,000	-	0.196	0.0068
P646	5,000	-	0.357	0.0247
P647	0	+	0.151	0.0158
P648	8	+	0.151	0.0332
P649	40	+	0.217	0.0596
P650	200	+	0.290	0.0226
P651	1,000	+	0.277	0.0919
P652	5,000	+	0.305	0.0545

Statistical Comparisons (ANOVA; $\alpha=0.05$)

P642, P643, P644, P645 vs P641: not significant

P646 vs P641: significant

P648 vs P647: not significant

P649, P650, P651, P652 vs P647: significant

P641 vs P647: not significant

P644 vs P650: significant

P642 vs P648: not significant

P645 vs P651: significant

P643 vs P649: not significant

P646 vs P652: not significant

ACC96-03p

-50-

Table 15: Anti-PnPs14 IgG response in Balb/c mice immunized with PnPs14-CRM₁₉₇ conjugate formulated with IL-12 and ALPO₄

Adjuvant Formulation		PnPs14 IgG Titers of Pooled Sera											
		IgG			IgG1			IgG2a			IgG2b		
IL-12 (ng)	ALPO ₄	Week 3	Week 5	Week 3	Week 5	Week 3	Week 5	Week 3	Week 5	Week 3	Week 5	Week 3	Week 5
0	-	1,691	24,498	479	9,967	139	492	<100	<100	<100	<100	295	1,516
8	-	4,679	32,966	841	9,860	377	1,902	108	609	390	1,354		
40	-	6,484	50,096	1,235	17,631	207	1,209	58	724	1,633	4,017		
200	-	5,330	51,240	385	7,568	715	3,748	290	1,397	1,091	4,519		
1,000	-	6,347	69,673	1,286	12,814	859	6,532	124	<100	782	6,208		
5,000	-	1,131	19,621	229	3,598	126	1,392	<100	<100	635	3,616		
0	+	7,825	103,092	1,714	38,147	195	1,535	617	3,973	447	2,963		
8	+	29,506	195,069	7,444	58,046	1,207	6,697	693	4,843	5,669	25,407		
40	+	35,567	295,361	4,945	46,030	2,883	17,267	1,371	9,911	5,797	22,602		
200	+	10,177	190,701	1,777	41,800	626	9,816	<100	1,479	3,443	23,648		
1,000	+	2,422	245,683	90	31,373	167	13,847	<100	722	1,173	34,039		
5,000	+	1,304	35,333	91	5,228	<100	1,429	<100	<100	772	8,065		

SUBSTITUTE SHEET (rule 26)

Table 16: Effect of IL-12 on the IgG response to PnPs14 in mice immunized with PnPs14-CRM₁₉₇ conjugate formulated with ALPO₄

Group	IL-12 (ng)	ALPO ₄	PnPs14 IgG GMT (fold increase)	
			Week 3	Week 5
P647	0	+	3,037	27,027
P648	8	+	16,68 (5.5)	55,855 (2.1)
P649	40	+	6,667 (2.2)	88,271 (3.4)
P650	200	+	2,333 (0.8)	57,076 (2.1)
P651	1,000	+	611 (0.2)	30,886 (1.1)
P652	5,000	+	617 (0.2)	10,989 (0.4)

Statistical Comparisons (ANOVA; $\alpha=0.05$)

Week 3 titers

P648 vs P647: significant

P651 vs P647: significant

P649, P650, P652 vs P647: not significant

Week 5 titers

P649 vs P647: significant

P648, P650, P651 vs P647: not significant

-52-

Table 17: PnPs14 IgG1 titers in mice twice immunized with PnPs14-CRM₁₉₇ conjugate vaccine formulated with or without AlPO₄ and various doses of IL-12

Adjuvant Formulation			
Group Code	IL-12 (ng)	AlPO ₄	IgG1 GMT (Geometric Mean Titer)
P641	0	-	9,492
P642	8	-	5,964
P643	40	-	14,028
P644	200	-	4,628
P645	1,000	-	5,815
P646	5,000	-	1,757
P647	0	+	15,283
P648	8	+	35,730
P649	40	+	31,855
P650	200	+	34,166
P651	1,000	+	15,347
P652	5,000	+	4,022

Statistical Comparisons (ANOVA; $\alpha=0.05$)

P642, P643, P644, P645, P646, P647, P651 vs P641:
not significant

P648, P649, P650 vs P641: significant

P648, P649, P650, P651 vs P647: not significant

P652 vs P647: significant

SUBSTITUTE SHEET (rule 26)

-53-

Table 18: PnPs14 IgG2a titers in mice twice immunized with PnPs14-CRM₁₉₇ conjugate vaccine formulated with or without AlPO₄ and various doses of IL-12

Group Code	IL-12 (ng)	AlPO ₄	IgG2a GMT at Week 5 (Fold Increase*)	
P641	0	-	97	
P642	8	-	1,418	(14.6)
P643	40	-	1,509	(15.6)
P644	200	-	2,228	(23.0)
P645	1,000	-	4,126	(42.5)
P646	5,000	-	289	(3.0)
P647	0	+	806	
P648	8	+	6,841	(8.5)
P649	40	+	13,252	(16.4)
P650	200	+	4,740	(5.9)
P651	1,000	+	3,291	(4.1)
P652	5,000	+	368	(0.5)

* relative to control vaccines not containing IL-12

Statistical Comparisons (ANOVA; $\alpha=0.05$)

P642, P643, P644, P645 vs P641: significant

P646 vs P641: not significant

P648, P649 vs P647: significant

P650, P651, P652 vs P647: not significant

P643 vs P649: significant

SUBSTITUTE SHEET (rule 26)

-54-

Table 19: Anti-CRM₁₉₇ IgG response in Balb/c mice immunized with PnPs14-CRM₁₉₇ conjugate formulated with IL-12 and AlPO₄

Adjuvant		CRM ₁₉₇ IgG Titer (Pooled Sera)		IgG Subclasses at Week 5 (Pooled Sera)		
IL-12 (ng)	AlPO ₄	Week 3	Week 5	IgG1	IgG2a	IgG2b
0	-	3,843	8,965	703	1,269	792
8	-	2,456	14,389	4,674	<100	<100
40	-	3,200	53,758	14,073	3,403	<100
200	-	1,666	13,419	1,803	2,044	<100
1,000	-	4,999	3,663	<100	506	<100
5,000	-	2,841	3,641	<100	<100	<100
0	+	4,870	153,075	55,922	1,796	407
8	+	89,558	1,515,87	377,82	85,972	10,972
40	+	19,566	1,319,10	147,03	199,29	7,206
200	+	6,884	315,071	48,852	36,807	3,865
1,000	+	7,292	545,827	126,72	44,190	4,127
5,000	+	7,213	7,029	1,041	769	<100

SUBSTITUTE SHEET (rule 26)

-55-

Table 20: IgG1 titers to CRM₁₉₇ in Balb/c mice immunized with PnPs14-CRM₁₉₇ conjugate formulated with IL-12 and AlPO₄

Group Code	IL-12 (ng)	AlPO ₄	IgG1 GMT	Fold Increase
P641	0	-	317	-
P642	8	-	1,136	3.6
P643	40	-	9,141	28.8
P644	200	-	1,627	5.1
P645	1,000	-	100	0.3
P646	5,000	-	174	0.6
P647	0	+	22,061	-
P648	8	+	119,130	5.4
P649	40	+	73,226	3.3
P650	200	+	14,391	0.7
P651	1,000	+	33,468	1.5
P652	5,000	+	317	0.01

Statistical Comparisons (ANOVA; $\alpha=0.05$)

P643, P644 vs P641: significant

P642, P645, P646 vs P641: not significant

P648, P649, P650, P651 vs P647: not significant

P642 vs P648, P643 vs P649, P644 vs P650, P645 vs P651:
significant

SUBSTITUTE SHEET (rule 26)

ACC96-03p

-56-

Table 21: Cytokine production by splenocytes from mice immunized twice with PnPS14-CRM₁₉₇ formulated with IL-12 in the presence and absence of ALPO₄

Cytokine	Cells Stimulated With		IL-12 Dose in Vaccine Formulated Without AlPO ₄ (ng)					IL-12 Dose in Vaccine Formulated With AlPO ₄ (ng)						
	Antigen	μg/mL	0	8	40	200	1,000	5,000	0	8	40	200	1,000	5,000
IFN-γ (U/mL)	CRM ₁₉₇	30	<0.06	<0.06	0.4	0.3	0.4	6.9	0.1	20.6	32.1	30.2	29.4	21.0
	CRM ₁₉₇	10	<0.06	<0.06	0.3	0.2	0.3	3.4	0.1	16.5	31.7	30.2	27.6	21.0
	CRM ₁₉₇	3	<0.06	<0.06	<0.06	<0.06	0.2	1.4	<0.03	15.7	30.9	28.7	26.7	20.1
	CRM ₁₉₇	1	<0.06	<0.06	<0.06	<0.06	0.2	0.4	<0.03	12.8	30.9	28.2	27.9	18.0
	CRM ₁₉₇	0.3	<0.06	<0.06	<0.06	<0.06	0.1	0.1	<0.03	6.3	27.5	26.2	26.5	6.5
	Lysozyme	30	<0.06	<0.06	<0.06	<0.06	<0.03	<0.03	<0.03	<0.0	<0.0	<0.0	<0.02	<0.02
	Con A	1	11.9	15.4	15.8	15.9	20.6	21.0	21.1	17.0	20.8	13.7	23.4	17.7
	Medium	-	<0.06	<0.06	<0.06	<0.06	<0.03	<0.03	<0.03	<0.0	<0.0	<0.0	<0.02	<0.02
IL-5 (pg/mL)	CRM ₁₉₇	30	370	480	2560	960	60	70	2010	1440	5280	1640	880	<10
	CRM ₁₉₇	10	150	300	1110	260	<24	<24	1220	920	4590	410	430	<10
	CRM ₁₉₇	3	30	90	910	200	<24	<24	1190	690	2830	1030	200	<10
	CRM ₁₉₇	1	<4	50	200	40	<24	<24	880	400	2150	520	140	<10
	CRM ₁₉₇	0.3	<4	30	70	<4	<24	<24	670	180	440	270	90	<10
	Lysozyme	30	<4	<4	<4	<4	<24	<24	<24	<24	<10	<10	<10	<10
	Con A	1	<4	<4	<4	<4	<24	<24	60	80	40	<10	<10	<10
	Medium	-	<4	<4	<4	<4	<24	<24	<24	<24	<10	<10	<10	<10

SUBSTITUTE SHEET (rule 26)

-57-

EXAMPLE 6: Effect of IL-12/AlPO₄ on the humoral response to a nonavalent pneumococcal glycoconjugate vaccine

STUDY DESIGN

5 Evaluation of the effect of IL-12 on the IgG response to pneumococcal glycoconjugate vaccine was extended to a nonavalent vaccine composed of serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F. Swiss Webster mice were immunized with 0.1, 1, or 5
10 μ g of vaccine (carbohydrate weight) at weeks 0 and 3. The vaccine was administered alone, with AlPO₄ (100 μ g) or with AlPO₄ admixed with 50, 200 or 1,000 ng of IL-12. Normal mouse serum was not included in the vaccine. The IgG responses to serotypes 4, 6B,
15 9V, 14, 18C and to the carrier protein CRM₁₉₇ were evaluated at week 5 (i.e., 2 weeks after boosting) by ELISA.

RESULTS

Response to CRM₁₉₇ at week 5

20 Addition of IL-12 to a vaccine containing AlPO₄ resulted in a dose-dependent increase in IgG2a and IgG2b antibodies to CRM₁₉₇. This was seen at all doses of conjugate tested (Table 22). Increased
25 IgG2a titers were evident in mice receiving 50 ng of the cytokine and were maximal at 1,000 ng. This

SUBSTITUTE SHEET (rule 26)

-58-

contrasts with other studies where maximal IgG2a titers were obtained with 40-100 ng of cytokine added to the alum-based vaccine and where higher doses of IL-12 resulted in a diminished immune response. The reason for the differences in dose response between studies is not known. It may relate to differences in the vaccine, i.e., multivalent versus monovalent or that normal mouse serum included in the vaccine in previous studies to stabilize the cytokine at low concentrations was omitted.

Response to pneumococcal polysaccharides

Formulating the nonavalent vaccine with AlP04 enhanced the IgG response to several serotypes including PnPs4, PnPs6B, PnPs9V and PnPs14, especially when the lowest dose of conjugate (0.1 µg) was used (Tables 24-27). Addition of IL-12 did not appear to further enhance the IgG response to these serotypes. In the case of the PnPs18C response, however, addition of 50 or 1,000 ng IL-12 to 5 µg of vaccine containing AlP04 resulted in higher geometric mean IgG titers to this serotype and higher proportion of mice with PnPs18C IgG titers above 10,000 (Table 23). The responses to PnPs1, 5, 19F and 23F were not evaluated.

Addition of IL-12 to nonavalent vaccines containing AlP04 resulted in dose-dependent increases in IgG2a titers to PnPs4, PnPs6B, PnPs9V

SUBSTITUTE SHEET (rule 26)

-59-

and PnPs14 (Tables 24-27). Generally, the increase in IgG2a paralleled that for the CRM₁₉₇ response with highest titers being obtained with 1,000 ng of IL-12. In contrast to the experiments using monovalent PnPs14 conjugate or bivalent PnPs6B/PnPs14 vaccine, the 50 ng dose of IL-12 had little or no effect on the IgG2a response to these serotypes. The exception is the IgG2a response to PnPs14, as this dose of cytokine appeared to enhance the response to this serotype (Table 27).

Overall, this study indicates that IL-12 will promote the complement-fixing IgG2a antibody subclass response to multiple pneumococcal serotypes present in a multivalent vaccine.

-60-

Table 22: Effect of IL-12 on the CRM₁₉₇ response of mice immunized with nonavalent pneumococcal glycoconjugate vaccine formulated with AlPO₄

5	Vaccine Formulation			CRM ₁₉₇ Response at Week 5				
	Conjugate Dose (µg)	IL-12 (ng)	AlPO ₄ (µg)	IgG	IgG1	IgG2a	IgG2b	IgG3
10	5.0	none	none	391,021	138,784	1,687	3,277	102
	5.0	0	100	1,419,910	609,704	4,328	11,349	181
	5.0	50	100	3,226,410	896,621	27,736	18,086	728
	5.0	200	100	2,991,990	584,991	87,732	28,855	2,937
	5.0	1,000	100	16,224,900	906,192	303,656	87,726	3,023
15	1.0	none	none	545,046	162,757	1,178	9,213	358
	1.0	0	100	956,584	338,751	1,284	4,118	306
	1.0	50	100	1,936,170	370,961	6,677	31,982	931
	1.0	200	100	4,788,500	660,082	187,034	36,785	1,065
	1.0	1,000	100	12,404,500	644,151	533,065	69,185	1,176
20	0.1	none	none	15,215	3,800	<100	<100	<100
	0.1	0	100	561,952	157,362	1,437	7,744	<100
	0.1	50	100	807,363	141,670	16,064	26,978	2,092
	0.1	200	100	1,560,380	313,263	38,686	51,737	306
	0.1	1,000	100	2,296,310	202,111	112,158	36,958	1,054

Mice were immunized with the indicated dose of nonavalent pneumococcal glycoconjugate vaccine at weeks 0 and 3.

The conjugates were formulated alone, with AlPO₄ (100 µg) or with AlPO₄ plus IL-12. Sera from the week 5 bleed were analyzed for IgG antibodies to CRM₁₉₇.

SUBSTITUTE SHEET (rule 26)

-61-

Table 23: Effect of IL-12 on the response to PnPs18C in mice immunized with 5 µg nonavalent pneumococcal glycoconjugate vaccine formulated with AlPO₄

Vaccine Formulation			PnPs18C Response	
Conjugate	IL-12	AlPO ₄	IgG Titer	Mice With Titer
Dose (µg)	(ng)	(µg)	(GMT)	>10,000 (n=5)
5	0	0	2,933	1
5	50	100	23,725	4
5	1,000	100	48,375	5

Mice were immunized with the indicated dose of nonavalent pneumococcal glycoconjugate vaccine at weeks 0 and 3. The conjugates were formulated alone, with AlPO₄ (100 µg) or with AlPO₄ plus IL-12. Individual mouse sera from the week 5 bleed were analyzed for IgG antibodies to PnPs18C.

-62-

Table 24: Effect of IL-12 on the PnPs4 response of mice immunized with nonavalent pneumococcal glycoconjugate vaccine formulated with AlP04

5	Vaccine Formulation			PnPs4 Response at Week 5				
	Conjugate Dose (μ g)	IL-12 (ng)	AlP0 ₄ (μ g)	IgG	IgG1	IgG2a	IgG2b	IgG3
10	5.0	none	none	55,068	13,731	<500	<500	<500
	5.0	0	100	233,008	55,620	<500	1,157	990
	5.0	50	100	285,806	64,493	1,050	1,329	2,634
	5.0	200	100	203,236	56,654	1,789	692	2,693
	5.0	1,000	100	371,329	35,778	4,048	1,080	3,820
15	1.0	none	none	77,714	9,070	<500	608	<500
	1.0	0	100	141,371	14,829	<500	<500	542
	1.0	50	100	97,999	14,336	449	814	1,034
	1.0	200	100	137,674	17,380	752	569	816
	1.0	1,000	100	214,739	25,056	4,685	1,260	4,055
20	0.1	none	none	4,726	706	<500	<500	<500
	0.1	0	100	79,686	12,071	<500	869	<500
	0.1	50	100	70,917	9,649	1,032	1,389	<500
	0.1	200	100	46,503	7,799	885	1,056	572
	0.1	1,000	100	87,762	6,788	1,725	<500	1,682

Mice were immunized with the indicated dose of nonavalent pneumococcal glycoconjugate vaccine at weeks 0 and 3. The conjugates were formulated alone, with AlP04 (100 μ g) or with AlP04 plus IL-12. Sera from the week 5 bleed were analyzed for IgG antibodies to PnPs4.

SUBSTITUTE SHEET (rule 26)

Table 25: Effect of IL-12 on the PnPs6B response of mice immunized with nonavalent pneumococcal glycoconjugate vaccine formulated with AlPO₄

5	Vaccine Formulation			PnPs6B Response at Week 5				
	Conjugate	IL-12	AlPO ₄	Total	IgG1	IgG2a	IgG2b	IgG3
	Dose (μg)	(ng)	(μg)	IgG				
10	5.0	none	none	64,734	20,221	<100	195	325
	5.0	0	100	103,686	39,061	138	2,498	1,801
	5.0	50	100	487,798	127,753	916	3,200	13,758
	5.0	200	100	214,743	59,979	924	959	6,459
	5.0	1,000	100	427,514	94,478	4,426	2,552	13,142
15	1.0	none	none	165,588	37,646	<100	2,047	2,337
	1.0	0	100	730,920	133,441	990	2,770	7,468
	1.0	50	100	428,549	77,124	838	3,755	12,931
	1.0	200	100	164,820	29,685	316	662	4,703
	1.0	1,000	100	401,513	51,132	11,44	2,735	31,613
20						2		
	0.1	none	none	4,787	1,034	<100	<100	<100
	0.1	0	100	370,177	71,287	603	11,372	5,712
	0.1	50	100	137,091	25,447	1,029	3,346	3,411
	0.1	200	100	128,428	31,634	434	2,698	1,891
	0.1	1,000	100	524,385	67,301	9,611	11,587	8,711

Mice were immunized with the indicated dose of nonavalent pneumococcal glycoconjugate vaccine at weeks 0 and 3. The conjugates were formulated alone, with AlPO₄ (100 μg) or with AlPO₄ plus IL-12. Sera from the week 5 bleed were analyzed for IgG antibodies to PnPs6B.

-64-

Table 26: Effect of IL-12 on the PnPs9V response of mice immunized with nonavalent pneumococcal glyconjugate vaccine formulated with AlPO4

	Vaccine Formulation			PnPs9V Response at Week 5				
	Conjugate Dose (μ g)	IL-12 (ng)	AlPO ₄ (μ g)	Total IgG	IgG1	IgG2a	IgG2b	IgG3
5	5.0	none	none	36,831	15,568	306	250	317
	5.0	0	100	78,614	37,544	359	667	286
	5.0	50	100	117,345	61,031	1,073	834	2,089
10	5.0	200	100	134,333	35,031	2,973	748	2,594
	5.0	1,000	100	197,407	40,368	15,353	2,147	1,945
	1.0	none	none	81,932	34,845	546	2,232	735
	1.0	0	100	100,448	55,608	660	1,274	699
	1.0	50	100	157,316	47,285	1,084	2,036	4,730
15	1.0	200	100	154,672	48,318	1,765	860	2,044
	1.0	1,000	100	168,614	54,223	10,037	1,469	3,006
	0.1	none	none	<500	181	<100	<100	<100
	0.1	0	100	86,952	26,425	206	485	1,285
	0.1	50	100	20,746	6,381	579	726	353
20	0.1	200	100	19,966	5,501	778	325	235
	0.1	1,000	100	50,219	3,511	1,290	1,036	714

Mice were immunized with the indicated dose of nonavalent pneumococcal glycoconjugate vaccine at weeks 0 and 3. The conjugates were formulated alone, with AlPO₄ (100 μ g) or with a AlPO₄ plus IL-12. Sera from the week 5 bleed were analyzed for IgG antibodies to PnPs9V.

SUBSTITUTE SHEET (rule 26)

-65-

Table 27: Effect of IL-12 on the PnPs14 response of mice immunized with nonavalent pneumococcal glyconjugate vaccine formulated with AlP04

5	Vaccine Formulation			PnPs14 Response at Week 5				
	Conjugate Dose (μ g)	IL-12 (ng)	AlPO ₄ (μ g)	Total IgG	IgG1	IgG2a	IgG2b	IgG3
10	5.0	none	none	2,676	1,750	<100	<100	<100
	5.0	0	100	11,792	15,704	124	580	1,723
	5.0	50	100	56,712	31,056	6,144	2,854	11,840
	5.0	200	100	5,049	3,050	1,588	<100	2,106
	5.0	1,000	100	11,848	3,760	1,853	366	2,035
15	1.0	none	none	4,846	3,116	<100	409	699
	1.0	0	100	20,605	31,022	291	2,383	9,286
	1.0	50	100	8,338	4,722	1,354	715	10,079
	1.0	200	100	5,618	3,252	1,014	<100	583
	1.0	1,000	100	13,026	3,551	2,879	671	2,070
20	0.1	none	none	<100	105	<100	<100	<100
	0.1	0	100	114	392	<100	<100	710
	0.1	50	100	2,140	2,838	<100	245	3,592
	0.1	200	100	2,200	426	<100	622	759
	0.1	1,000	100	394	378	219	100	658

Mice were immunized with the indicated dose of nonavalent pneumococcal glycoconjugate vaccine at weeks 0 and 3. The conjugates were formulated alone, with AlP04 (100 μ g) or with AlP04 plus IL-12. Sera from the week 5 bleed were analyzed for IgG antibodies to PnPs14.

SUBSTITUTE SHEET (rule 26)

-66-

EXAMPLE 7: The effect of IL-12 and AlP04 on the
immune response to *Neisseria meningitidis*
type C (menC) glyconconjugate vaccine

STUDY DESIGN

5 This study evaluated IL-12 with a vaccine against
Neisseria meningitidis type C (menC). Swiss Webster mice
were immunized at weeks 0 and 3 with 0.1 µg or 1 µg of
MenC glycoconjugate formulated alone, with AlP0₄ (100 µg)
or a combination of IL-12 (50 ng) and AlP04. Normal
10 mouse serum was not added to the vaccine. Mice were bled
at weeks 3 and 5 and sera analyzed for IgG antibodies to
menC polysaccharide by ELISA.

RESULTS

15 When immunized with the higher dose of conjugate,
equivalent menC IgG titers were generated regardless of
the adjuvant formulation. The addition of IL-12/AlP04 to
the vaccine, however, resulted in higher IgG2a titers to
the polysaccharide than if formulated with AlP04 (but no
IL-12) or no adjuvant.

20 In mice immunized with the lower dose of conjugate,
higher mening C titers were obtained when the vaccine was
formulated with AlP04 (Table 28). The addition of IL-12
to the adjuvant did not enhance the overall IgG titer but
did result in a >10-fold increase in IgG2a antibodies.
25 These data show that IL-12 in combination with AlP04 can
promote the induction of complement-fixing IgG subclasses
to menC glyconconjugate vaccine.

SUBSTITUTE SHEET (rule 26)

-67-

Table 28: Effect of IL-12/AlPO₄ on the IgG response to menC glyconconjugate vaccine

Vaccine Formulation			MenC Response					
			IgG		IgG Subclass at Week 5			
MenC Conjugate (μ g)	IL-12 (ng)	AlPO ₄ (μ g)	Week 3	Week 5	IgG1	IgG2a	IgG2b	IgG3
1.0	50	100	33,176	598,027	83,662	7,218	4,351	1,436
	0	100	34,553	404,111	71,017	1,383	3,085	1,006
	0	0	16,254	288,493	63,043	1,965	<100	502
0.1	50	100	2,584	68,678	9,604	3,440	1,967	512
	0	100	8,174	30,450	6,532	288	429	<100
	0	0	1,724	7,894	1,767	<100	<100	<100

SUBSTITUTE SHEET (rule 26)

-68-

Example 8: The effect of IL-12 and Alp04 on the immune response to *Hemophilus influenzae* type b glyconconjugate vaccine (HbOC)

STUDY DESIGN

5 This study evaluated IL-12 with a vaccine against *Hemophilus influenzae* type b. Swiss Webster mice (10 per group) were immunized at weeks 0 and 3 with 0.1 µg or 1.0 µg of glyconconjugate vaccine consisting of capsular polysaccharide from *Hemophilus influenzae* type b (HibPs) conjugated to CRM₁₉₇. The vaccine (HbOC) was administered alone or in combination with Alp04 (100 µg) or a mixture of IL-12 (50 ng) plus Alp04. Normal mouse serum was not added to the vaccine. The mice were bled at weeks 3 and 5. The antibody response to HibPs was measured using a Farr assay which measures all antibodies binding to the saccharide regardless of isotype, i.e., IgM, IgG and IgA. The IgG subclass response was measured by ELISA. Additionally, the IgG and IgG subclass response to CRM₁₉₇ was also determined by ELISA.

20 RESULTS

The titers of anti-HibPs antibodies in serum pooled from the week 3 bleed (primary response) were not different between mice immunized with vaccine formulated alone, with Alp04 or IL-12 plus Alp04 regardless of the dose of conjugate used for immunization (Table 29). Analysis of pooled serum from the week 5 bleed suggested

SUBSTITUTE SHEET (rule 26)

-69-

that in mice immunized with 1 µg of HbOC with IL-12 plus alum resulted in at least a 10-fold higher anti-HibPs than when given with alum or without adjuvant (Table 30). However, analysis of individual mouse sera showed that this was due to a single mouse having a titer of approximately 10,000 µg/mL. When the results are expressed as geometric mean titer there was no evidence of an enhanced HibPs response due to IL-12. The IgG subclass response to HibPs was evaluated on pooled sera by ELISA. The combination of IL-12 and AlP04 appeared to enhance the IgG2a titer 3-fold in mice immunized with 1 µg of conjugate. However, this was no different than the titer obtained with vaccine adjuvanted with AlP04 alone. In mice immunized with 0.1 µg of HbOC, IL-12 plus AlP04 did not enhance the IgG2a titer to HibPs. That the IL-12/AlP04 adjuvant combination was active was revealed by analysis of the anti-CRM₁₉₇ response (Table 31) where increased IgG2a titer to the carrier protein was seen in mice immunized with either dose of conjugate.

SUBSTITUTE SHEET (rule 26)

-70-

Table 29: Anti-HibPs antibody response of mice immunized with HbOC formulated with IL-12 and AlPO₄

			Anti-HibPs Antibody Response ($\mu\text{g/mL}$)		
Vaccine Formulation			Week 3	Week 5	
HbOC (μg)	IL-12 (ng)	AlPO ₄ (μg)	Pooled Serum	Pooled Serum	GMT*
1.0	50	100	9.73	469.16	26.92
	0	100	10.04	42.55	21.30
	0	0	5.12	33.19	2.25
0.1	50	100	3.18	30.95	ND
	0	100	4.06	15.11	ND
	0	0	3.03	14.05	ND

SUBSTITUTE SHEET (rule 26)

-71-

Table 30: Effect of IL-12 and AlPO₄ on the IgG subclass response to HbOC

Vaccine Formulation			Anti-HibPs IgG Subclass Response at Week 5 (ELISA Endpoint Titer)	
HbOC (μ g)	IL-12 (ng)	AlPO ₄ (μ g)	IgG1	IgG2a
1.0	50	100	754,745	26,899
	0	100	122,637	12,880
	0	0	73,114	8,570
0.1	50	100	46,673	17,290
	0	100	68,176	14,971
	0	0	35,237	11,418

SUBSTITUTE SHEET (rule 26)

-72-

Table 31: Anti-CRM₁₉₇ IgG response of mice immunized with HbOC formulated with IL-12 and AlPO₄

Vaccine Formulation			Anti-CRM ₁₉₇ Response at Week 5			
HbOC (μ g)	IL-12 (ng)	AlPO ₄ (μ g)	IgG	IgG1	IgG2a	IgG2b
1.0	50	100	1,775,700	681,944	39,672	40,527
	0	100	2,221,780	818,557	19,010	32,672
	0	0	3,979,530	1,466,010	8,059	15,961
0.1	50	100	761,027	292,448	38,258	21,008
	0	100	891,251	346,728	6,546	14,832
	0	0	874,805	151,397	1,899	3,517

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

The claims defining the invention are as follows:

1. A vaccine composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum and optionally comprising a physiologically acceptable vehicle.
- 5 2. A vaccine composition according to claim 2, wherein the interleukin-12 is adsorbed onto the mineral suspension.
3. A vaccine composition according to claim 1 or claim 2, wherein the interleukin-12 is human interleukin-12.
4. A vaccine composition according to any one of claims 1 to 3, wherein the
10 alum is aluminum hydroxide or aluminum phosphate.
5. A vaccine composition according to any one of claims 1 to 4, wherein the pneumococcal antigen is selected from the group consisting of pneumococcal capsular polysaccharide serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F and combinations thereof.
6. A vaccine composition according to any one of claims 1 to 5, wherein the
15 pneumococcal antigen is conjugated to a carrier molecule.
7. A vaccine composition according to claim 6, wherein the carrier molecule is selected from the group consisting of tetanus toxin, diphtheria toxin, pertussis toxin and non-toxic variants thereof.
8. A vaccine composition according to claim 7, wherein the carrier molecule is
20 CRM₁₉₇.
9. A method of eliciting an immune response to a pneumococcal antigen, comprising administering to a mammalian host an effective amount of a vaccine composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a
25 physiologically acceptable vehicle.
10. A method according to claim 9, wherein the interleukin-12 is adsorbed onto the mineral suspension.
11. A method according to claim 9 or claim 10, wherein the interleukin-12 is human interleukin-12.
12. A method according to any one of claims 9 to 11, wherein the alum is aluminum hydroxide or aluminum phosphate.
13. A method according to any one of claims 9 to 12, wherein the pneumococcal antigen is selected from the group consisting of pneumococcal capsular polysaccharide serotypes 1, 4, 5, 6B, 9v, 14, 18C, 19F and 23F and combinations thereof.



14. A method according to any of claims 9 to 13, wherein the pneumococcal antigen is conjugated to a carrier molecule.

15. A method according to claim 14, wherein the carrier molecule is selected from the group consisting of tetanus toxin, diphtheria toxin, pertussis toxin and non-toxic variants thereof.

16. A method according to claim 15, wherein the carrier molecule is CRM₁₉₇.

17. A method of enhancing IFN- γ response to a pneumococcal vaccine, comprising administering to a mammalian host an effective amount of a vaccine composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

18. A method of eliciting complement-fixing antibodies for a protective response to a pathogen, comprising administering to a mammalian host an effective amount of an immunogenic composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

19. An immunogenic composition comprising a mixture of a pneumococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

20. An immunogenic composition according to claim 19, wherein the interleukin-12 is adsorbed onto the mineral suspension.

21. An immunogenic composition according to claim 21 or claim 22, wherein the interleukin-12 is human interleukin-12.

22. An immunogenic composition according to any one of claims 19 to 21, wherein the alum is aluminum hydroxide or aluminum phosphate.

23. An immunogenic composition according to any one of claims 19 to 22, wherein the pneumococcal antigen is selected from the group consisting of pneumococcal capsular polysaccharide serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F and combinations thereof.

24. An immunogenic composition according to any one of claims 19 to 23, wherein the pneumococcal antigen is conjugated to a carrier molecule.

25. An immunogenic composition according to claim 24, wherein the carrier molecule is selected from the group consisting of tetanus toxin, diphtheria toxin, pertussis toxin and non-toxic variants thereof.



26. An immunogenic composition according to claim 25, wherein the carrier molecule is CRM₁₉₇.

27. A vaccine composition comprising a mixture of a meningococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

28. A vaccine composition according to claim 27, where the interleukin-12 is adsorbed onto the mineral suspension.

29. A vaccine composition according to claim 27 or claim 28, wherein the interleukin-12 is human interleukin-12.

30. A vaccine composition according to any one of claims 27 to 29, wherein the alum is aluminum hydroxide or aluminum phosphate.

31. A vaccine composition according to any one of claims 27 to 30, wherein the meningococcal antigen is the *Neisseria meningitidis* type C capsular polysaccharide.

32. A vaccine composition according to any one of claims 27 to 31, wherein the meningococcal antigen is conjugated to a carrier molecule.

33. A vaccine composition according to claim 32, wherein the carrier molecule is selected from the group consisting of tetanus toxin, diphtheria toxin, pertussis toxin and non-toxic variants thereof.

34. A vaccine composition according to claim 33, wherein the carrier molecule is CRM₁₉₇.

35. A method of eliciting an immune response to a meningococcal antigen, comprising administering to a mammalian host an effective amount of a vaccine composition comprising a mixture of a meningococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

36. A method according to claim 35, wherein the interleukin-12 is adsorbed onto the mineral suspension.

37. A method according to claim 35 or claim 36, wherein the interleukin-12 is human interleukin-12.

38. A method according to claim 37, wherein the alum is aluminum hydroxide or aluminum phosphate.

39. A method according to claim 37 or claim 38, wherein the meningococcal antigen is the *Neisseria meningitidis* type C capsular polysaccharide.

40. A method according to any one of claims 37 to 39, wherein the meningococcal antigen is conjugated to a carrier molecule.



41. A method according to claim 40, wherein the carrier molecule is selected from the group consisting of tetanus toxin, diphtheria toxin, pertussis toxin and non-toxic variants thereof.

42. A method according to claim 41, wherein the carrier molecule is CRM₁₉₇.

5 43. An immunogenic composition comprising a mixture of a meningococcal antigen, an adjuvant amount of interleukin-12 and a mineral suspension comprising alum, and optionally comprising a physiologically acceptable vehicle.

44. An immunogenic composition according to claim 43, wherein the interleukin-12 is adsorbed onto the mineral suspension.

10 45. An immunogenic composition according to claim 43 or claim 44 wherein the interleukin-12 is human interleukin-12.

46. An immunogenic composition according to any one of claims 43 to 45, wherein the alum is aluminum hydroxide or aluminum phosphate.

47. An immunogenic composition according to any one of claims 43 to 46,
15 wherein the meningococcal antigen is the *Neisseria meningitidis* type C capsular polysaccharide.

48. An immunogenic composition according to any one of claims 43 to 47, wherein the meningococcal antigen is conjugated to a carrier molecule.

20 49. An immunogenic composition according to claim 48, wherein the carrier molecule is selected from the group consisting of tetanus toxin, diphtheria toxin, pertussis toxin and non-toxic variants thereof.

50. An immunogenic composition according to claim 49, wherein the carrier molecule is CRM₁₉₇.

51. A vaccine composition as set out in claim 1, substantially as hereinbefore
25 described with reference to any one of the Examples 1 to 6 or 8.

52. An immunogenic composition as set out in claim 19, substantially as hereinbefore described with reference to any one of Examples 1 to 6 or 8.

53. A vaccine composition as set out in claim 27, substantially as hereinbefore described with reference to Example 7.

30 54. An immunogenic composition as set out in claim 43, substantially as hereinbefore described with reference to Example 7.

55. A vaccine composition according to any one of claims 1 to 8 or 51, when used in a method of eliciting an immune response to a pneumococcal antigen.

56. A vaccine composition according to any one of claims 1 to 8 or 51, when used in a method of enhancing IFN- γ response to a pneumococcal vaccine.



57. A vaccine composition according to any one of claims 1 to 8 or 51, when used in a method of eliciting compliment-fixing antibodies for a protective response to a pathogen.

58. A vaccine composition according to any one of claims 27 to 34 or claim 53,
5 when used method of eliciting an immune response to a meningococcal antigen.

59. A process for producing a composition according to any one claims 1 to 8, 19 to 34, 43 to 50 or 51 to 55 substantially as hereinbefore described with reference to any one of the examples.

Dated 6 February 2003
American Cyanamid Company

10

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON

